<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis - Murray, A - 2020 | Cochrane Library</title> <meta content="Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis - Murray, A - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000544.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis - Murray, A - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000544.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000544.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis" name="citation_title"/> <meta content="Alistair Murray" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Tran M Nguyen" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Claire E Parker" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Brian G Feagan" name="citation_author"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="jmacdon1@uwo.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD000544.pub5" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000544.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000544.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000544.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Aminosalicylic Acids [*administration &amp; dosage]; Anti-Inflammatory Agents, Non-Steroidal [*administration &amp; dosage, adverse effects]; Bias; Colitis, Ulcerative [*drug therapy, prevention &amp; control]; Drug Administration Schedule; Maintenance Chemotherapy [*methods]; Medication Adherence [statistics &amp; numerical data]; Mesalamine [*administration &amp; dosage]; Patient Dropouts [statistics &amp; numerical data]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Recurrence; Remission Induction [methods]; Sulfasalazine [administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000544.pub5&amp;doi=10.1002/14651858.CD000544.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000544\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000544\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ko","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000544.pub5",title:"Oral 5\\u2010aminosalicylic acid for maintenance of remission in ulcerative colitis",firstPublishedDate:"Aug 28, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000544.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000544.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000544.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000544.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000544.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000544.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000544.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000544.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000544.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000544.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5797 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000544.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/appendices#CD000544-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/table_n/CD000544StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/table_n/CD000544StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#CD000544-cr-0004">Alistair Murray</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#CD000544-cr-0005">Tran M Nguyen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#CD000544-cr-0006">Claire E Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#CD000544-cr-0007">Brian G Feagan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information#CD000544-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>John K MacDonald</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information/en#CD000544-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000544.pub5">https://doi.org/10.1002/14651858.CD000544.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000544-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000544-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000544-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000544-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000544-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000544-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000544-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000544-abs-0001" lang="en"> <section id="CD000544-sec-0001"> <h3 class="title" id="CD000544-sec-0001">Background</h3> <p>Oral 5‐aminosalicylic acid (5‐ASA; also known as mesalazine or mesalamine) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. In an earlier version of this review, we found that 5‐ASA drugs were more effective than placebo for maintenance of remission of ulcerative colitis (UC), but had a significant therapeutic inferiority relative to SASP. In this version, we have rerun the search to bring the review up to date. </p> </section> <section id="CD000544-sec-0002"> <h3 class="title" id="CD000544-sec-0002">Objectives</h3> <p>To assess the efficacy, dose‐responsiveness, and safety of oral 5‐ASA compared to placebo, SASP, or 5‐ASA comparators for maintenance of remission in quiescent UC and to compare the efficacy and safety of once‐daily dosing of oral 5‐ASA with conventional (two or three times daily) dosing regimens. </p> </section> <section id="CD000544-sec-0003"> <h3 class="title" id="CD000544-sec-0003">Search methods</h3> <p>We performed a literature search for studies on 11 June 2019 using MEDLINE, Embase, and the Cochrane Library. In addition, we searched review articles and conference proceedings. </p> </section> <section id="CD000544-sec-0004"> <h3 class="title" id="CD000544-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials with a minimum treatment duration of six months. We considered studies of oral 5‐ASA therapy for treatment of participants with quiescent UC compared with placebo, SASP, or other 5‐ASA formulations. We also included studies that compared once‐daily 5‐ASA treatment with conventional dosing of 5‐ASA and 5‐ASA dose‐ranging studies. </p> </section> <section id="CD000544-sec-0005"> <h3 class="title" id="CD000544-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. The primary outcome was the failure to maintain clinical or endoscopic remission. Secondary outcomes were adherence, adverse events (AE), serious adverse events (SAE), withdrawals due to AEs, and withdrawals or exclusions after entry. Trials were separated into five comparison groups: 5‐ASA versus placebo, 5‐ASA versus SASP, once‐daily dosing versus conventional dosing, 5‐ASA (balsalazide, Pentasa, and olsalazine) versus comparator 5‐ASA formulation (Asacol and Salofalk), and 5‐ASA dose‐ranging. We calculated the risk ratio (RR) and 95% confidence interval (CI) for each outcome. We analyzed data on an intention‐to‐treat basis, and used GRADE to assess the overall certainty of the evidence. </p> </section> <section id="CD000544-sec-0006"> <h3 class="title" id="CD000544-sec-0006">Main results</h3> <p>The search identified 44 studies (9967 participants). Most studies were at low risk of bias. Ten studies were at high risk of bias. Seven of these studies were single‐blind and three were open‐label. </p> <p>5‐ASA is more effective than placebo for maintenance of clinical or endoscopic remission. About 37% (335/907) of 5‐ASA participants relapsed at six to 12 months compared to 55% (355/648) of placebo participants (RR 0.68, 95% CI 0.61 to 0.76; 8 studies, 1555 participants; high‐certainty evidence). Adherence to study medication was not reported for this comparison. SAEs were reported in 1% (6/550) of participants in the 5‐ASA group compared to 2% (5/276) of participants in the placebo group at six to 12 months (RR 0.60, 95% CI 0.19 to 1.84; 3 studies, 826 participants; low‐certainty evidence). There is probably little or no difference in AEs at six to 12 months' follow‐up (RR 0.93, 95% CI 0.73 to 1.18; 5 studies, 1132 participants; moderate‐certainty evidence). </p> <p>SASP is more effective than 5‐ASA for maintenance of remission. About 48% (416/871) of 5‐ASA participants relapsed at six to 18 months compared to 43% (336/784) of SASP participants (RR 1.14, 95% CI 1.03 to 1.27; 12 studies, 1655 participants; high‐certainty evidence). Adherence to study medication and SAEs were not reported for this comparison. There is probably little or no difference in AEs at six to 12 months' follow‐up (RR 1.07, 95% CI 0.82 to 1.40; 7 studies, 1138 participants; moderate‐certainty evidence). </p> <p>There is little or no difference in clinical or endoscopic remission rates between once‐daily and conventionally dosed 5‐ASA. About 37% (717/1939) of once‐daily participants relapsed over 12 months compared to 39% (770/1971) of conventional‐dosing participants (RR 0.94, 95% CI 0.88 to 1.01; 10 studies, 3910 participants; high‐certainty evidence). There is probably little or no difference in medication adherence rates. About 10% (106/1152) of participants in the once‐daily group failed to adhere to their medication regimen compared to 8% (84/1154) of participants in the conventional‐dosing group (RR 1.18, 95% CI 0.72 to 1.93; 9 studies, 2306 participants; moderate‐certainty evidence). About 3% (41/1587) of participants in the once‐daily group experienced a SAE compared to 2% (35/1609) of participants in the conventional‐dose group at six to 12 months (RR 1.20, 95% CI 0.77 to 1.87; moderate‐certainty evidence). There is little or no difference in the incidence of AEs at six to 13 months' follow‐up (RR 0.98, 95% CI 0.92 to 1.04; 8 studies, 3497 participants; high‐certainty evidence). </p> <p>There may be little or no difference in the efficacy of different 5‐ASA formulations. About 44% (158/358) of participants in the 5‐ASA group relapsed at six to 18 months compared to 41% (142/349) of participants in the 5‐ASA comparator group (RR 1.08, 95% CI 0.91 to 1.28; 6 studies, 707 participants; low‐certainty evidence). </p> </section> <section id="CD000544-sec-0007"> <h3 class="title" id="CD000544-sec-0007">Authors' conclusions</h3> <p>There is high‐certainty evidence that 5‐ASA is superior to placebo for maintenance therapy in UC. There is high‐certainty evidence that 5‐ASA is inferior compared to SASP. There is probably little or no difference between 5‐ASA and placebo, and 5‐ASA and SASP in commonly reported AEs such as flatulence, abdominal pain, nausea, diarrhea, headache, and dyspepsia. Oral 5‐ASA administered once daily has a similar benefit and harm profile as conventional dosing for maintenance of remission in quiescent UC. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000544-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000544-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000544-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000544-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000544-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000544-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000544-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000544-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD000544-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000544-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000544-abs-0002" lang="en"> <h3>Oral 5‐aminosalicylic acid compounds for maintaining remission in ulcerative colitis</h3> <p><b>What was the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out if oral 5‐aminosalicylic acid (also known as mesalazine or mesalamine) helps maintain remission and prevent relapse in people with ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease that results in long‐lasting inflammation of the colon. Some common symptoms include bloody diarrhea, abdominal and rectal pain, weight loss, fatigue and fever. The review authors collected and analyzed all relevant studies to answer this question and found 44 studies. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to June 2019.</p> <p><b>What was studied in the review?</b> </p> <p>The researchers examined whether oral 5‐aminosalicylic acid was better than a placebo (a fake medication), other comparator 5‐aminosalicylic acid formulations, sulfasalazine, different dose levels of oral 5‐aminosalicylic acid, and once‐daily dosing compared to conventional dosing in people with ulcerative colitis. The outcomes included clinical or endoscopic (where a long, thin tube is directly entered into the bowel) remission, adherence to medication regimen, and side effects from the medication. </p> <p><b>What were the main results of the review?</b> </p> <p>The review authors found 44 relevant studies (9967 participants). These studies compared oral 5‐aminosalicylic medications to placebo, comparator 5‐aminosalicylic acid formulations, sulfasalazine, different dose levels of oral 5‐aminosalicylic acid, and once‐daily dosing compared to conventional dosing. </p> <p>Eight studies (1555 participants) assessed the effectiveness of oral 5‐aminosalicylic acid compared to placebo. The studies found oral 5‐aminosalicylic acid was more effective than placebo for maintaining clinical or endoscopic remission (high‐certainty evidence). Twelve studies (1655 participants) assessed the effectiveness of sulfasalazine compared to 5‐aminosalicylic acid. The studies found sulfasalazine to be slightly more effective compared to 5‐aminosalicylic acid (high‐certainty evidence). Ten studies (3910 participants) assessed the effectiveness of once‐daily compared to conventional dosing (twice daily). The studies found there was probably no difference between the groups for maintaining clinical or endoscopic remission (moderate‐certainty evidence). An additional analysis of adherence to study medication was also done on once‐daily versus conventional dosing. The results showed there was probably no difference in adherence to taking medication between the two dosing groups (moderate‐certainty evidence). Six studies (1781 participants) assessed oral 5‐aminosalicylic acid (e.g. balsalazide, Pentasa, and olsalazine) compared to other 5‐aminosalicylic acid formulations (e.g. Asacol and Salofalk). The studies found there was probably no difference in clinical or endoscopic remission between the 5‐aminosalicylic acid and the 5‐aminosalicylic acid comparator groups (low‐certainty evidence). </p> <p>There is probably little or no evidence of a difference in commonly reported side effects between 5‐aminosalicylic acid and any of the comparators. Commonly reported side effects included flatulence, abdominal pain, nausea, diarrhea, headache, dyspepsia (indigestion), and nasopharyngitis (inflammation of the nasal passages). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000544-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000544-sec-0092"></div> <h3 class="title" id="CD000544-sec-0093">Implications for practice</h3> <section id="CD000544-sec-0093"> <p>It is clear that oral 5‐aminosalicylic acid (5‐ASA) preparations have yet to be proven to be more clinically beneficial than sulfasalazine (SASP). Male infertility is associated with SASP and not with 5‐ASA (<a href="./references#CD000544-bbs2-0111" title="KjaergaardN , Ambrosius ChristensenL , LauritsenJG , RasmussenN , Honore HansenS . Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis. Scandinavian Journal of Gastroenterology1989;24:891-6.">Kjaergaard 1989</a>; <a href="./references#CD000544-bbs2-0124" title="RileySA , LecarpentierJ , MiniV , GoodmanJJ , MandalBK , TurnbergLA . Sulfasalazine induced seminal abnormalities in ulcerative colitis: result of mesalazine substitution. Gut1987;28:1008-12.">Riley 1987</a>), so 5‐ASA may be preferred for patients concerned about fertility. 5‐ASA therapy is more expensive than SASP, so SASP may be the preferred option where cost is an important factor. Patients who are intolerant to SASP may prefer 5‐ASA. Oral 5‐ASA administered once daily is as effective and safe as conventional dosing (twice or three times daily) for maintenance of remission in quiescent ulcerative colitis. Once‐daily dosing does not appear to enhance adherence in the clinical trial setting. There may be little or no difference in efficacy or safety between the various formulations of 5‐ASA. When selecting among the various 5‐ASA formulations, physicians and patients should consider dose‐response data, adherence issues, and price (<a href="./references#CD000544-bbs2-0126" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>). </p> </section> <h3 class="title" id="CD000544-sec-0094">Implications for research</h3> <section id="CD000544-sec-0094"> <p>With limited research funding, careful thought should be given prior to commissioning new trials of 5‐ASA preparations for the treatment of quiescent ulcerative colitis. Future trials comparing 5‐ASA with placebo or SASP may not be justified. There does not appear to be any difference in efficacy or safety between the various formulations of 5‐ASA. However, the overall certainty of the evidence from the studies examining differences in efficacy between various 5‐ASA formulations was low due to sparse data and risk of bias. Future trials should look at enhancing patient adherence with medication. Adherence to therapy is important for treatment success and may be an important predictor of relapse. Future trials could assess whether once‐daily dosing regimens improve adherence in the community. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000544-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000544-sec-0008"></div> <div class="table" id="CD000544-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus placebo for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral 5‐ASA vs placebo for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent UC<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> oral 5‐ASA<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/>(334 to 416) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b><br/>(0.61 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1555<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission defined using the revised SDAI (rectal bleeding = 0, mucosal appearance ≤ 2). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b><br/>(292 to 472) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/>(0.73 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1132<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events included headache, nausea, abdominal pain, dyspepsia, bloating, influenza syndrome, rhinitis, diarrhea, and nasopharyngitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> <p>(3 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.19 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>826</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included UC aggravation, acute pancreatitis, moderate ventricular dysfunction, intestinal obstruction, and esophagitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse event</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(34 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/>(0.76 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1454<br/>(7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included UC aggravation diarrhea, headache, and paresthesia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b> </p> <p>(162 to 266)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> </p> <p>(0.88 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1074</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SDAI:</b> Sutherland Disease Activity Index; <b>UC:</b> ulcerative colitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious imprecision (478 events).<br/><sup>b</sup>Downgraded two levels due to very serious imprecision (11 events).<br/><sup>c</sup>Downgraded one level due to serious imprecision (70 events).<br/><sup>d</sup>Downgraded one level due to serious imprecision (202 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000544-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus sulfasalazine for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral 5‐ASA vs SASP for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent ulcerative colitis<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> oral 5‐ASA<br/><b>Comparison:</b> SASP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SASP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>489 per 1000</b><br/>(441 to 544) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/>(1.03 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1655<br/>(12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or endoscopic remission defined as the absence of colitis symptoms together with an absence of inflammation on sigmoidoscopy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b><br/>(130 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> <br/>(0.82 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1138<br/>(7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Commonly reported adverse events in the SASP‐controlled trials included: headache, anorexia or appetite loss, nausea, vomiting, abdominal pain, dyspepsia, excessive flatus, bloating, urticaria, and rash. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse event</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/>(47 to 102) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> <br/>(0.87 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1585<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included diarrhea, abdominal pain, indigestion, and rash. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> <p>(160 to 251)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b> </p> <p>(1.04 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1497</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SASP:</b> sulfasalazine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision (182 events).<br/><sup>b</sup>Downgraded one level due to imprecision (97 events).<br/><sup>c</sup>Downgraded one level due to imprecision (259 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000544-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Once‐daily dosing versus conventional dosing for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Once‐daily dosing vs conventional dosing for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent UC<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> OD oral 5‐ASA<br/><b>Comparison:</b> conventional dosing of 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Conventionally dosed oral <b>5</b>‐ASA </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>OD oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 12–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b><br/>(344 to 395) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.88 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3910<br/>(10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or endoscopic remission defined as a mucosal score of 0 or 1 (endoscopic remission), or a bloody stool score of 0 and an UC‐DAI &lt; 2/Simple Clinical Colitis Activity Index score of ≤ 2 points (clinical remission). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication regimen</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b><br/>(52 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/>(0.72 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2306<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence to medication regimen calculated using objective data (pill count or pharmacy data) in 6/9 studies in the analysis. 2 studies used participant self‐report to calculate adherence and 1 study did not describe how adherence was assessed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>481 per 1000</b><br/>(451 to 510) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/>(0.92 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3497<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events included flatulence, dyspepsia, abdominal pain, nausea, diarrhea, headache, nasopharyngitis, inflammation of the upper respiratory tract, gastroenteritis. dental caries, and worsening of UC. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> <p>(17 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> </p> <p>(0.77 to 1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3196</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included UC aggravation, acute pancreatitis, anal fistula, pneumonia, melena, nephrolithiasis, and hypersensitivity pneumonitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(11 to 27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/>(0.74 to 1.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4340<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included UC aggravation, flatulence, nausea, and abdominal distension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> <p>(127 to 172)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> </p> <p>(0.85 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3737</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>OD:</b> once daily; <b>RR:</b> risk ratio; <b>SDAI:</b> Sutherland Disease Activity Index; <b>UC:</b> ulcerative colitis; <b>UC‐DAI:</b> Ulcerative Colitis Disease Activity Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision (190 events).<br/><sup>b</sup>Downgraded one level due to imprecision (76 events).<br/><sup>c</sup>Downgraded one level due to imprecision (67 events).<br/><sup>d</sup>Downgraded two levels due to risk of bias (two studies open label and high risk of bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000544-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus comparator 5‐aminosalicylic acid formulation for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral 5‐ASA vs comparator 5‐ASA formulation for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent UC<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> oral 5‐ASA (balsalazide, Pentasa and olsalazine)<br/><b>Comparison:</b> comparator oral 5‐ASA (Asacol and Salofalk) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator Oral 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>407 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b><br/>(370 to 521) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.91 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>707<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or endoscopic remission was defined as either the Harvey Bradshaw Index (score &lt; 3) and by a sigmoidoscopy (score 0–1) or the absence of symptoms or the presence of only mild symptoms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>686 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>645 per 1000</b><br/>(569 to 734) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.83 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events included dyspepsia, abdominal pain, nausea, distension, diarrhea, headache, nasopharyngitis or respiratory infections, influenza‐like disorder, and rash. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> <p>(15 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b> </p> <p>(0.14 to 2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events reported included urinary tract infection, severe complication of UC, cardiac arrest, ischemic heart, fracture of the scaphoid, and spigelian hernia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><br/>(25 to 124) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> <br/>(0.0.56 to 2.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included headache, lethargy, hypertension, malaise, and abdominal pain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> </p> <p>(200 to 378)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> </p> <p>(0.90 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>OD:</b> once daily; <b>RR:</b> risk ratio; <b>SDAI:</b> Sutherland Disease Activity Index; <b>UC:</b> ulcerative colitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious imprecision (300 events).<br/><sup>b</sup>Downgraded one level due to risk of bias. Two studies in pooled analysis were single blind and one was open label.<br/><sup>c</sup>Downgraded one level due to serious imprecision (236 events).<br/><sup>d</sup>Downgraded one level due to risk of bias. One study in the pooled analysis was open label.<br/><sup>e</sup>Downgraded two levels due to serious imprecision (8 events).<br/><sup>f</sup>Downgraded two levels due to very serious imprecision (23 events).<br/><sup>g</sup>Downgraded one level due to risk of bias. One study in the pooled analysis due was single blind and another was open label.<br/><sup>h</sup>Downgraded one level due to imprecision (114 events). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000544-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000544-sec-0009"></div> <section id="CD000544-sec-0010"> <h3 class="title" id="CD000544-sec-0010">Description of the condition</h3> <p>Ulcerative colitis (UC) is an inflammatory bowel condition that results in long‐lasting inflammation of the colon. Some common symptoms of UC include diarrhea, abdominal and rectal pain, weight loss and fatigue. In addition to these symptoms, approximately 6% to 47% of patients also experience extraintestinal manifestations affecting the eyes, joints, liver, and skin. These manifestations may include arthritis, uveitis, oral ulcers, and primary sclerosing cholangitis (<a href="./references#CD000544-bbs2-0125" title="RothfussKS , StangeEF , HerrlingerKR . Extraintestinal manifestations and complications in inflammatory bowel diseases. World Journal of Gastroenterology2006;12(30):4819-31.">Rothfuss 2006</a>). The pathogenesis of UC is unknown; however, there are genetic and environmental factors that have been correlated with the increased risk. UC is more common in the industrialized world, especially in North America and Western Europe. The overall worldwide incidence is 1.2 to 20.3 cases per 100,000 people per year, with a prevalence of 7.6 to 245 cases per 100,000 people per year (<a href="./references#CD000544-bbs2-0091" title="DaneseS , FiocchiC . Ulcerative colitis. New England Journal of Medicine2011;365(18):1713-25.">Danese 2011</a>; <a href="./references#CD000544-bbs2-0114" title="LoftusEJ . Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology2004;126(6):1504-17.">Loftus 2004</a>). In North America, the prevalence of UC ranges from 120 to 250 cases per 100,000 people and the incidence ranges from 8 to 20 cases per 100,000 people (<a href="./references#CD000544-bbs2-0114" title="LoftusEJ . Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology2004;126(6):1504-17.">Loftus 2004</a>). </p> <p>Treatments for UC may include biological therapies (adalimumab, infliximab, vedolizumab, golimumab, ustekinumab), corticosteroids, azathioprine or 6‐mercaptopurine, and 5‐aminosalicylic acids (5‐ASA; also known as mesalazine or mesalamine). For people with mild‐to‐moderate UC, 5‐ASAs and corticosteroids are the standard treatment for induction of remission. This is followed by thiopurines, anti‐tumor necrosis factor (anti‐TNF) drugs, or adhesion molecule inhibitors for moderate‐to‐severe UC (<a href="./references#CD000544-bbs2-0095" title="FeuersteinJD , CheifetzAS . Ulcerative colitis. Mayo Clinic Proceedings2014;89(11):1553-63.">Feuerstein 2014</a>). </p> </section> <section id="CD000544-sec-0011"> <h3 class="title" id="CD000544-sec-0011">Description of the intervention</h3> <p>The successful management of UC was greatly facilitated after the introduction of sulfasalazine (SASP) by Svartz (<a href="./references#CD000544-bbs2-0133" title="SvartzN . Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Medica Scandinavica1942;110:557-90.">Svartz 1942</a>). SASP is composed of 5‐ASA linked to sulfapyridine via a diazo bond. This bond is readily cleaved by bacterial azoreductases in the colon to yield the two components (<a href="./references#CD000544-bbs2-0120" title="PeppercornMA , GoldmanP . The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. Journal of Pharmacology and Experimental Therapeutics1972;181:555-62.">Peppercorn 1972</a>). Of these, 5‐ASA is the therapeutically active component, while sulfapyridine, which is primarily absorbed into systemic circulation, is assumed to function solely as a carrier molecule (<a href="./references#CD000544-bbs2-0087" title="Azad KhanAK , PirisJ , TrueloveSC . An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet1977;2(8044):892-5.">Azad Khan 1977</a>; <a href="./references#CD000544-bbs2-0112" title="KlotzU , MaierK , FischerC , HeinkelK . Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New England Journal of Medicine1980;303:1499-502.">Klotz 1980</a>; <a href="./references#CD000544-bbs2-0136" title="Van HeesPA , BakkerJH , TongerenJH . Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut1980;21:632-5.">Van Hees 1980</a>). </p> </section> <section id="CD000544-sec-0012"> <h3 class="title" id="CD000544-sec-0012">How the intervention might work</h3> <p>Administration of unbound or uncoated 5‐ASA revealed that it was readily absorbed in the upper jejunum and was unable to reach the colon in therapeutic concentrations (<a href="./references#CD000544-bbs2-0117" title="MyersB , EvansDN , RhodesJ , EvansBK , HughesBR , LeeMG , et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut1987;28:196-200.">Myers 1987</a>; <a href="./references#CD000544-bbs2-0119" title="NielsenOH , BondesenS . Kinetics of 5-aminosalicylic acid after jejunal instillation in man. British Journal of Clinical Pharmacology1983;16:738-40.">Nielsen 1983</a>; <a href="./references#CD000544-bbs2-0130" title="SchroederH , CampbellDE . Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics1972;13:539-51.">Schroeder 1972</a>). Ingested SASP largely resists such premature absorption and thus is able to serve as a delivery system that transports 5‐ASA to the affected regions of the lower intestinal tract (<a href="./references#CD000544-bbs2-0130" title="SchroederH , CampbellDE . Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics1972;13:539-51.">Schroeder 1972</a>). While corticosteroid therapy is more effective in the treatment of severe UC (<a href="./references#CD000544-bbs2-0134" title="TrueloveSC , WittsLJ . Cortisone in ulcerative colitis: final report on a therapeutic trial. British Medical Journal1955;4947:1041-8.">Truelove 1955</a>; <a href="./references#CD000544-bbs2-0135" title="TrueloveSC , WittsLJ . Cortisone and corticotrophin in ulcerative colitis. British Medical Journal1959;i:387-94.">Truelove 1959</a>), the use of SASP in maintaining remission has been well established (<a href="./references#CD000544-bbs2-0116" title="MisiewitzJJ , Lennard-JonesJE , ConnellAM , BaronJH , JonesFA . Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet1965;1:185-8.">Misiewitz 1965</a>). </p> <p>Despite its benefits, up to 30% of people receiving SASP have reported adverse effects (AE) (<a href="./references#CD000544-bbs2-0118" title="NielsenOH . Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology1982;17:389-93.">Nielsen 1982</a>). It was concluded that many were due to the sulfapyridine moiety, especially those effects found to be dose‐dependent (<a href="./references#CD000544-bbs2-0092" title="DasKM , EastwoodMA , McManusJP , SircusW . Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. New England Journal of Medicine1973;289:491-5.">Das 1973</a>; <a href="./references#CD000544-bbs2-0117" title="MyersB , EvansDN , RhodesJ , EvansBK , HughesBR , LeeMG , et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut1987;28:196-200.">Myers 1987</a>). This discovery spawned more than a decade of research aimed at finding alternative 5‐ASA delivery systems. </p> <p>Asacol® (Proctor and Gamble) consists of a pellet of 5‐ASA destined for release in the terminal ileum or colon due to a coating known as Eudragit‐S, a resin that dissolves at a pH greater than 7 (<a href="./references#CD000544-bbs2-0093" title="DewMJ , HughesPJ , LeeMG , EvansBK , RhodesJ . An oral preparation to release drugs in the human colon. British Journal of Clinical Pharmacology1982;14:405-8.">Dew 1982a</a>). Claversal® or Mesasal® (GlaxoSmithKline), Salofalk® (Axcan Pharma, Falk Foundation), and Rowasa® (Reid‐Rowell) are similar delayed‐release preparations of 5‐ASA pellets coated with Eudragit L, a resin that dissolves at a pH greater than 6 (the approximate pH of the ileum/colon) (<a href="./references#CD000544-bbs2-0101" title="HardyJG , HealeyJN , ReynoldsJR . Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics1987;1:273-80.">Hardy 1987</a>; <a href="./references#CD000544-bbs2-0117" title="MyersB , EvansDN , RhodesJ , EvansBK , HughesBR , LeeMG , et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut1987;28:196-200.">Myers 1987</a>). Pentasa® (Marion‐Merrell‐Dow) is a microsphere formulation that consists of 5‐ASA microgranules enclosed within a semi‐permeable membrane of ethylcellulose. It is designed for controlled release that begins in the duodenum and continues into the affected regions of the lower bowel (<a href="./references#CD000544-bbs2-0122" title="RasmussenSN , BondesenS , HvidbergEF , HansenSH , BinderV , HalskouS , et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology1982;83:1062-70.">Rasmussen 1982</a>). Olsalazine or Dipentum® (Pharmacia &amp; Upjohn) consists of two 5‐ASA molecules linked by a diazo bond (<a href="./references#CD000544-bbs2-0076" title="Staerk LaursenL , StokholmM , BukhaveK , Rask-MadsenJ , LauritsenK . Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut1990;31:1271-6. ">Staerk Laursen 1990</a>; <a href="./references#CD000544-bbs2-0137" title="WilloughbyCP , AronsonJK , AgbackH , BodinNO , TrueloveSC . Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut1982;23:1081-7.">Willoughby 1982</a>). Other formulations, such as benzalazine and balsalazide, are composed of 5‐ASA molecules azo‐bonded to various benzoic acid derivatives (<a href="./references#CD000544-bbs2-0090" title="ChanRP , PopeDJ , GilbertAP , SacraPJ , BaronJH , Lennard-JonesJE . Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digestive Diseases and Sciences1983;28:609-15.">Chan 1983</a>; <a href="./references#CD000544-bbs2-0096" title="FleigWE , LaudageG , SommerH , WellmannW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80.">Fleig 1988</a>). Like SASP, these compounds are poorly absorbed in the upper digestive tract but are readily metabolized by the intestinal flora in the lower bowel. MMX mesalamine (Lialdaa® or Mezavanta®) uses Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon (<a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>). </p> <p>The newer 5‐ASA preparations were intended to avoid the AEs of SASP while maintaining its therapeutic benefits. These drugs are more costly, however, and still cause AEs in some patients (<a href="./references#CD000544-bbs2-0121" title="RaoSS , CannPA , HoldsworthCD . Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulfasalazine. Scandinavian Journal of Gastroenterology1987;22:332-6.">Rao 1987</a>). The efficacy and safety of the 5‐ASA preparations have been evaluated in numerous clinical trials that have often lacked sufficient statistical power to arrive at definitive conclusions. In an earlier meta‐analysis, <a href="./references#CD000544-bbs2-0139" title="SutherlandLR , MayGR , ShafferEA . Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine1993;118:540-9.">Sutherland 1993</a> found that the newer 5‐ASA drugs were no more effective than SASP for maintenance of remission in UC. This systematic review is an update of the Cochrane Review published in 2012 (<a href="./references#CD000544-bbs2-0138" title="FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub3]">Feagan 2012</a>). We proceeded with this updated review, in accordance with the format of Cochrane, to include the more recent studies as well as to evaluate the effectiveness, dose‐responsiveness, and safety of the 5‐ASA preparations in terms of more precise outcome measures. </p> <p>Many patients are non‐adherent with conventional multi‐dose (two or three times daily) treatment regimens, which may result in reduced efficacy and can lead to an increased risk of relapse in people with quiescent disease (<a href="./references#CD000544-bbs2-0107" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000544-bbs2-0108" title="KaneS , HuoD , AikensJ , HanauerS . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine2003;114(1):39-43.">Kane 2003a</a>), poor long‐term prognosis (<a href="./references#CD000544-bbs2-0110" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008a</a>), and increased costs of care (<a href="./references#CD000544-bbs2-0088" title="Beaulieu DB SchwartzDA . Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes CME. MedScape CME Gastroenterology Posted 22 December 2009.">Beaulieu 2009</a>; <a href="./references#CD000544-bbs2-0110" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008a</a>). Poor adherence may be particularly problematic in quiescent disease (<a href="./references#CD000544-bbs2-0107" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000544-bbs2-0108" title="KaneS , HuoD , AikensJ , HanauerS . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine2003;114(1):39-43.">Kane 2003a</a>), since patients lack continuing symptoms that incentivize them to take medication. Although multiple factors influence medication adherence in people with UC, it is commonly believed that a high pill burden and multi‐dose regimens are major determinants (<a href="./references#CD000544-bbs2-0094" title="EdigerJP , WalkerJR , GraffL , LixL , ClaraI , RawsthorneP , et al. Predictors of medication adherence in inflammatory bowel disease. American Journal of Gastroenterology2007;102(7):1417-26.">Ediger 2007</a>; <a href="./references#CD000544-bbs2-0110" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008a</a>). Accordingly, it is reasonable to hypothesize that once‐daily dosing of 5‐ASA might improve both adherence with maintenance therapy and outcomes. </p> </section> <section id="CD000544-sec-0013"> <h3 class="title" id="CD000544-sec-0013">Why it is important to do this review</h3> <p>This review was performed to assess the evidence supporting the use of oral 5‐ASA for the maintenance of remission in people with UC. The efficacy and safety of oral 5‐ASA compared to placebo, oral 5‐ASA compared to different formulations, and once‐daily compared to conventional dosing for the treatment of UC. Many of these trials were small and lacked sufficient statistical power to arrive at definitive conclusions. This systematic review is an update of a previously published Cochrane Review and includes three new studies (<a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0041" title="SuzukiY , lidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000544-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000544-sec-0014"></div> <p>To assess the efficacy, dose‐responsiveness, and safety of oral 5‐ASA compared to placebo, SASP, or 5‐ASA comparators for maintenance of remission in quiescent UC and to compare the efficacy and safety of once‐daily dosing of oral 5‐ASA with conventional (two or three times daily) dosing regimens. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000544-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000544-sec-0015"></div> <section id="CD000544-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000544-sec-0017"> <h4 class="title">Types of studies</h4> <p>Prospective, randomized controlled trials of parallel design, with a minimum treatment duration of six months. </p> </section> <section id="CD000544-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants of any age with mild‐to‐moderate UC in remission as defined by Truelove and Witts (<a href="./references#CD000544-bbs2-0134" title="TrueloveSC , WittsLJ . Cortisone in ulcerative colitis: final report on a therapeutic trial. British Medical Journal1955;4947:1041-8.">Truelove 1955</a>). </p> </section> <section id="CD000544-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials of oral 5‐ASA therapy for treatment of participants with UC in remission compared with placebo, SASP, or other formulations of 5‐ASA. We also considered studies that compared once‐daily 5‐ASA treatment with conventional dosing of 5‐ASA (two or three times daily) and 5‐ASA dose‐ranging studies. </p> </section> <section id="CD000544-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Outcome measures included endoscopic or clinical relapse, or early withdrawal, as defined by the authors of each study. </p> <section id="CD000544-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD000544-list-0001"> <li> <p>Endoscopic or clinical relapse as defined by the authors of each study.</p> </li> </ol> </p> </section> <section id="CD000544-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD000544-list-0002"> <li> <p>Adherence with medication regimen.</p> </li> <li> <p>Adverse events (AE).</p> </li> <li> <p>Serious adverse events (SAE).</p> </li> <li> <p>Withdrawal due to AEs.</p> </li> <li> <p>Exclusion of withdrawal after entry.</p> </li> </ol> </p> </section> </section> </section> <section id="CD000544-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000544-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched MEDLINE, Embase, the Cochrane library (CENTRAL), the Cochrane IBD Specialized Register, and clinicaltrials.gov from inception to 11 June 2019. We applied no language or document type restrictions. The search strategy is listed in <a href="./appendices#CD000544-sec-0097">Appendix 1</a>. </p> </section> <section id="CD000544-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched review articles and conference abstracts to identify additional studies.</p> </section> </section> <section id="CD000544-sec-0026"> <h3 class="title" id="CD000544-sec-0026">Data collection and analysis</h3> <section id="CD000544-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AM and TN) independently selected relevant studies for analysis based on the prespecified inclusion criteria. We discussed disagreements between review authors and reached agreement by consensus. When necessary, we contacted the original authors to clarify outcomes and trial methodology. </p> </section> <section id="CD000544-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AM and TN) independently extracted data using a standard data extraction form. We recorded results using an intention‐to‐treat (ITT) basis and settled any discrepancies between review authors by consensus. We extracted baseline characteristics (sex, age, disease location, disease duration), intervention type (dose, administration), comparator (no intervention, placebo, active comparator), and prespecified primary and secondary outcomes. </p> </section> <section id="CD000544-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AM and TN) independently assessed the risk of bias in the included studies using the Cochrane 'Risk of bias' tool (<a href="./references#CD000544-bbs2-0103" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). Factors assessed included: </p> <p> <ol id="CD000544-list-0003"> <li> <p>sequence generation (i.e. was the allocation sequence adequately generated?);</p> </li> <li> <p>allocation sequence concealment (i.e. was allocation adequately concealed?);</p> </li> <li> <p>blinding (i.e. was knowledge of the allocated intervention adequately prevented during the study?); </p> </li> <li> <p>incomplete outcome data (i.e. were incomplete outcome data adequately addressed?);</p> </li> <li> <p>selective outcome reporting (i.e. are reports of the study free of suggestion of selective outcome reporting?); and </p> </li> <li> <p>other potential sources of bias (i.e. was the study apparently free of other problems that could put it at a high risk of bias?). </p> </li> </ol> </p> <p>A judgement of 'yes' indicated low risk of bias, 'no' indicated high risk of bias, and 'unclear' indicated unclear or unknown risk of bias. We resolved disagreements by consensus. We contacted study authors when there was insufficient information to determine risk of bias. </p> </section> <section id="CD000544-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (CI). We pooled the results for each comparison group to determine the RR and 95% CI for each outcome resulting from 5‐ASA therapy relative to placebo, SASP, or 5‐ASA comparator; and once‐daily 5‐ASA therapy relative to conventional dosing. We used a fixed‐effect model. We pooled studies for analysis if participants, outcomes, and interventions were similar (determined by consensus among authors). We pooled studies comparing 5‐ASA formulations for analysis if they compared equimolar doses of oral 5‐ASA. For continuous outcomes, we planned to calculate the mean difference (MD) if studies used the same scale, or standardized mean difference (SMD) if studies used different scales, both with 95% CI. </p> </section> <section id="CD000544-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For trials with multiple arms (e.g. different dose groups), we divided the placebo group across subgroups so that independent comparisons could be performed between each subgroup and the split placebo group (<a href="./references#CD000544-bbs2-0104" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). To avoid potential carry‐over effects, we only used data from before the first cross‐over for any included cross‐over studies. For outcomes that were measured at different time points, we determined the appropriate fixed intervals for follow‐up (<a href="./references#CD000544-bbs2-0104" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). For recurring events (i.e. AEs), we used the proportion of participants who had at least one event for analysis. There were no cluster randomized trials. </p> </section> <section id="CD000544-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We analyzed missing dichotomous outcomes according to the ITT principle. Participants with missing data were assumed to be treatment failures. Alternatively, for continuous outcomes, we used the number of participants who completed the trial and did not impute any missing variables. </p> </section> <section id="CD000544-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the presence of heterogeneity among studies using the Chi² test (a P value of 0.10 was statistically significant) and the I² statistic (<a href="./references#CD000544-bbs2-0102" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327:557-60.">Higgins 2003</a>). If there was statistically significant heterogeneity, we calculated the RR and 95% CI using a random‐effects model. We did not pool data in a meta‐analysis if there was a high degree of heterogeneity (e.g. I² greater than 75%). </p> </section> <section id="CD000544-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We compared the outcomes listed in the study protocols to the outcomes listed in the final manuscripts. However, if we could not locate the protocol, we compared the outcomes listed in the methods section to the outcomes in the results section. If there was a sufficient number of studies included (i.e. more than 10) in the pooled analyses, we planned to use a funnel plot to investigate a potential publication bias. </p> </section> <section id="CD000544-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Trials made five comparisons: 5‐ASA versus placebo, 5‐ASA versus SASP, once‐daily dosing versus conventional dosing, 5‐ASA versus comparator 5‐ASA, and 5‐ASA dose‐ranging. We pooled data from studies where the intervention, participant groups, and outcomes were similar. We pooled the RR and 95% CI for dichotomous outcomes and the MD or SMD and corresponding 95% CI for continuous outcomes. </p> </section> <section id="CD000544-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analyses.</p> <p> <ol id="CD000544-list-0004"> <li> <p>Once‐daily versus conventional dosing studies subgrouped by formulation.</p> </li> <li> <p>5‐ASA‐controlled trials subgrouped by common 5‐ASA comparators (e.g. Asacol, Claversal, Salofalk, and Pentasa). </p> </li> <li> <p>Dose‐ranging studies subgrouped by 5‐ASA formulation.</p> </li> <li> <p>Subgrouped according to the specific 5‐ASA preparation for those outcomes for which there were two or more studies that used a similar drug. </p> </li> </ol> </p> </section> <section id="CD000544-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses as appropriate to investigate heterogeneity. We also conducted sensitivity analyses excluding studies with a high risk of bias. All statistical analyses were performed using the Cochrane Review Manager 5 software package (<a href="./references#CD000544-bbs2-0123" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD000544-sec-0038"> <h4 class="title">'Summary of findings' tables</h4> <p>We used the GRADE approach for rating the overall certainty of the evidence for the primary outcomes and selected secondary outcomes of interest. Randomized trials start as high‐certainty evidence, but may be downgraded due to: </p> <p> <ol id="CD000544-list-0005"> <li> <p>limitations in design and implementation (risk of bias);</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>inconsistency (unexplained heterogeneity);</p> </li> <li> <p>imprecision (sparse data); and</p> </li> <li> <p>reporting bias (publication bias).</p> </li> </ol> </p> <p>The overall certainty of the evidence for each outcome was determined after considering each of these elements, and categorized as high certainty (i.e. further research is very unlikely to change our confidence in the estimate of effect); moderate certainty (i.e. further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); low certainty (i.e. further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); and very‐low certainty (i.e. we are very uncertain about the estimate) (<a href="./references#CD000544-bbs2-0100" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>; <a href="./references#CD000544-bbs2-0131" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). </p> <p>For the 'Summary of findings' tables, we included the following outcomes: endoscopic or clinical relapse, failure to adhere with study medication, at least one AEs, at least one SAEs, withdrawal due to AEs and exclusion/withdrawal after entry. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000544-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000544-sec-0039"></div> <section id="CD000544-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD000544-sec-0041"> <h4 class="title">Results of the search</h4> <p>The literature search conducted on 11 June 2019 identified 3331 studies. We identified 20 additional studies through searching of references. After removal of duplicates, 2321 reports remained for review of titles and abstracts. After reviewing the titles and abstracts of these studies, we selected 132 reports of oral 5‐ASA maintenance treatment for quiescent UC for full‐text review (<a href="#CD000544-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD000544-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000544-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD000544-sec-0042"> <h4 class="title">Included studies</h4> <p>We included 88 reports of 44 studies involving 9967 participants (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0007" title="DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal1983;287:23-4. DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut1983;24(Suppl 10):A983. ">Dew 1983</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a>; <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a>; <a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0015" title="HawkeyCJ , DubeLM , RountreeLV , LinnenPJ , LancasterJF , the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology1997;112:718-24. ">Hawkey 1997</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0018" title="ItoH , IidaM , MatsumotoT , SuzukiY , AidaY , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1575-82. ">Ito 2010</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a>; <a href="./references#CD000544-bbs2-0021" title="KaneS , HoldermanW , JacquesP , MiodekT . Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence2008;2(2):253-8. ">Kane 2008b</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>; <a href="./references#CD000544-bbs2-0039" title="JarnerotG , Sandberg-GertzenH . Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study. Gastroenterology1985;88(5 Part 2):A1432. Sandberg-GertzenH , JarnerotG , KraazW . Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology1986;90:1024-30. ">Sandberg‐Gertzen 1986</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>; <a href="./references#CD000544-bbs2-0041" title="SuzukiY , lidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>; <a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>) (see <a href="./references#CD000544-sec-0107" title="">Characteristics of included studies</a> table). </p> <p>Eight studies were placebo‐controlled (<a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0015" title="HawkeyCJ , DubeLM , RountreeLV , LinnenPJ , LancasterJF , the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology1997;112:718-24. ">Hawkey 1997</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0039" title="JarnerotG , Sandberg-GertzenH . Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study. Gastroenterology1985;88(5 Part 2):A1432. Sandberg-GertzenH , JarnerotG , KraazW . Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology1986;90:1024-30. ">Sandberg‐Gertzen 1986</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). Twelve studies compared 5‐ASA to SASP (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0007" title="DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal1983;287:23-4. DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut1983;24(Suppl 10):A983. ">Dew 1983</a>; <a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>). Twelve studies were maintenance of remission studies comparing once‐daily dosing of 5‐ASA with conventional dosing (<a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a>; <a href="./references#CD000544-bbs2-0021" title="KaneS , HoldermanW , JacquesP , MiodekT . Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence2008;2(2):253-8. ">Kane 2008b</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>; <a href="./references#CD000544-bbs2-0041" title="SuzukiY , lidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). Six studies compared the efficacy and safety of various formulations of oral 5‐ASA to other formulations of oral 5‐ASA for maintenance treatment (<a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0018" title="ItoH , IidaM , MatsumotoT , SuzukiY , AidaY , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1575-82. ">Ito 2010</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>). Ten trials were dose‐ranging studies of oral 5‐ASA (<a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a>; <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a>; <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>; <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a>; <a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>). Six studies were formal non‐inferiority studies (<a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0018" title="ItoH , IidaM , MatsumotoT , SuzukiY , AidaY , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1575-82. ">Ito 2010</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). </p> </section> <section id="CD000544-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 39 reports with reasons (see <a href="./references#CD000544-sec-0108" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD000544-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias assessment is provided in <a href="#CD000544-fig-0002">Figure 2</a>. Most of the included studies were of high methodological quality. Ten studies were at high risk of bias. </p> <div class="figure" id="CD000544-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD000544-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD000544-sec-0045"> <h4 class="title">Allocation</h4> <p>Nineteen studies did not describe methods used for allocation concealment and were rated as unclear for this item (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0007" title="DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal1983;287:23-4. DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut1983;24(Suppl 10):A983. ">Dew 1983</a>; <a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a>; <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a>; <a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>; <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a>; <a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). The remaining studies were at low risk of allocation bias. </p> <p>Thirty of 43 included studies did not describe the method used for randomization and were rated as unclear for this item (<a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0007" title="DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal1983;287:23-4. DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut1983;24(Suppl 10):A983. ">Dew 1983</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a>; <a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0015" title="HawkeyCJ , DubeLM , RountreeLV , LinnenPJ , LancasterJF , the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology1997;112:718-24. ">Hawkey 1997</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>; <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>; <a href="./references#CD000544-bbs2-0039" title="JarnerotG , Sandberg-GertzenH . Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study. Gastroenterology1985;88(5 Part 2):A1432. Sandberg-GertzenH , JarnerotG , KraazW . Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology1986;90:1024-30. ">Sandberg‐Gertzen 1986</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>; <a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). The remaining studies were at low risk of randomization bias. </p> </section> <section id="CD000544-sec-0046"> <h4 class="title">Blinding</h4> <p>Seven studies were single‐blind with a blinded investigator assessing outcomes (<a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a>; <a href="./references#CD000544-bbs2-0021" title="KaneS , HoldermanW , JacquesP , MiodekT . Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence2008;2(2):253-8. ">Kane 2008b</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>). Three studies were open‐label and investigators and participants were not blinded to treatment assignment (<a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>; <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a>). However, two open‐label studies (<a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>), and four of seven single‐blind studies (<a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0021" title="KaneS , HoldermanW , JacquesP , MiodekT . Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence2008;2(2):253-8. ">Kane 2008b</a>), utilized investigator‐performed endoscopy as an endpoint, which may protect against bias provided the endoscopist is blinded. The methods used for blinding were not described in one study and this study was rated as unclear (<a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>). The remaining studies were at low risk of performance and detection bias. </p> </section> <section id="CD000544-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Thirteen studies were at unclear risk for incomplete outcome data because reasons for withdrawal were not described (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0007" title="DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal1983;287:23-4. DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut1983;24(Suppl 10):A983. ">Dew 1983</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>; <a href="./references#CD000544-bbs2-0039" title="JarnerotG , Sandberg-GertzenH . Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study. Gastroenterology1985;88(5 Part 2):A1432. Sandberg-GertzenH , JarnerotG , KraazW . Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology1986;90:1024-30. ">Sandberg‐Gertzen 1986</a>; <a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>). </p> </section> <section id="CD000544-sec-0048"> <h4 class="title">Selective reporting</h4> <p>All studies were at low risk of bias for selective reporting.</p> </section> <section id="CD000544-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>All studies appeared free from other potential sources of bias.</p> </section> </section> <section id="CD000544-sec-0050"> <h3 class="title" id="CD000544-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD000544-tbl-0001"><b>Summary of findings 1</b> Oral 5‐aminosalicylic acid versus placebo for maintenance of remission in ulcerative colitis</a>; <a href="./full#CD000544-tbl-0002"><b>Summary of findings 2</b> Oral 5‐aminosalicylic acid versus sulfasalazine for maintenance of remission in ulcerative colitis</a>; <a href="./full#CD000544-tbl-0003"><b>Summary of findings 3</b> Once‐daily dosing versus conventional dosing for maintenance of remission in ulcerative colitis</a>; <a href="./full#CD000544-tbl-0004"><b>Summary of findings 4</b> Oral 5‐aminosalicylic acid versus comparator 5‐aminosalicylic acid formulation for maintenance of remission in ulcerative colitis</a> </p> <section id="CD000544-sec-0051"> <h4 class="title">5‐Aminosalicylic acid versus placebo</h4> <section id="CD000544-sec-0052"> <h5 class="title">Endoscopic or clinical relapse</h5> <p>Eight trials (1555 participants) reported treatment outcomes in terms of failure to maintain clinical or endoscopic remission (<a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0015" title="HawkeyCJ , DubeLM , RountreeLV , LinnenPJ , LancasterJF , the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology1997;112:718-24. ">Hawkey 1997</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0039" title="JarnerotG , Sandberg-GertzenH . Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study. Gastroenterology1985;88(5 Part 2):A1432. Sandberg-GertzenH , JarnerotG , KraazW . Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology1986;90:1024-30. ">Sandberg‐Gertzen 1986</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). At six to 12 months, 37% (335/907) of 5‐ASA participants relapsed compared to 52% (335/648) of placebo participants (RR 0.68, 95% CI 0.61 to 0.76; I² = 10%; high‐certainty evidence; <a href="./references#CD000544-fig-0003" title="">Analysis 1.1</a>). There was a trend towards greater efficacy with higher doses of 5‐ASA with a benefit for the 1 g/day to 1.9 g/day (RR 0.65, 95% CI 0.56 to 0.75; I² = 0%) and the 2 g/day or greater subgroups (RR 0.73, 95% CI 0.60 to 0.89; I² = 71%). The pooled RR was similar when calculated exclusively with those trials with endpoints at 12 months (RR 0.68, 95% CI 0.61 to 0.76) (<a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). Two trials involving olsalazine had a pooled RR of 0.76 (95% CI 0.58 to 0.99) (<a href="./references#CD000544-bbs2-0039" title="JarnerotG , Sandberg-GertzenH . Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study. Gastroenterology1985;88(5 Part 2):A1432. Sandberg-GertzenH , JarnerotG , KraazW . Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology1986;90:1024-30. ">Sandberg‐Gertzen 1986</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). Two trials involving Asacol (<a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>), had a pooled RR of 0.73 (95% CI 0.60 to 0.88). See <a href="./full#CD000544-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD000544-sec-0053"> <h5 class="title">Adherence to medication regimen</h5> <p>None of the studies reported adherence to medication regimen.</p> </section> <section id="CD000544-sec-0054"> <h5 class="title">Adverse events</h5> <p>Five studies (1132 participants) reported the proportion of participants who experienced at least one AE (<a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). There was no difference in the incidence of AEs between 5‐ASA and placebo participants at six to 12 months. About 44% (306/702) of 5‐ASA participants experienced at least one AE compared to 40% (172/430) of placebo participants (RR 0.93, 95% CI 0.73 to 1.18; I² = 56%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0004" title="">Analysis 1.2</a>). The heterogeneity appeared to be a result of the inclusion of one specific trial (<a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a> reported a significantly higher AE rate in the 5‐ASA group compared to placebo, mostly due to a high rate of olsalazine‐related diarrhea in the 5‐ASA group. To investigate if this study was the source of the heterogeneity, we repeated the analysis excluding this trial. The pooled analysis of the ITT population now included four studies and 1031 participants (<a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>). Overall, 45% (294/653) of 5‐ASA participants experienced at least one AE compared to 45% (170/378) of placebo participants (RR 0.91, 95% CI 0.79 to 1.06; I² = 12%; <a href="./references#CD000544-fig-0005" title="">Analysis 1.3</a>). Commonly reported AEs in the placebo‐controlled trials included: headache, nausea, abdominal pain, dyspepsia, bloating, influenza syndrome, rhinitis, diarrhea, and nasopharyngitis. See <a href="./full#CD000544-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD000544-sec-0055"> <h5 class="title">Serious adverse events</h5> <p>Three studies (826 participants) reported SAEs (<a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>). About 1% (6/550) of participants in the 5‐ASA group compared to 2% (5/276) of participants in the placebo group at six to 12 months had at least one SAE (RR 0.60, 95% CI 0.19 to 1.84; I² = 0%; low‐certainty evidence; <a href="./references#CD000544-fig-0006" title="">Analysis 1.4</a>). Reported SAEs included UC aggravation, acute pancreatitis, moderate ventricular dysfunction, intestinal obstruction, and esophagitis. See <a href="./full#CD000544-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD000544-sec-0056"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Seven studies (1454 participants) reported the proportion of participants withdrawn due to AEs (<a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0015" title="HawkeyCJ , DubeLM , RountreeLV , LinnenPJ , LancasterJF , the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology1997;112:718-24. ">Hawkey 1997</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). There were withdrawals due to AEs for 5% (43/855) of 5‐ASA participants compared to 5% (27/599) of placebo participants at six to 12 months (RR 1.22, 95% CI 0.76 to 1.95; I² = 37%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0007" title="">Analysis 1.5</a>). The heterogeneity appeared to be a result of the inclusion of one specific trial (<a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). To investigate if this study was the source of the heterogeneity, we repeated the analysis excluding this trial. The pooled analysis of the ITT population now included six studies and 1353 participants (<a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0011" title="GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , BarrettAC , et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology2016;50(4):318-25. ">Gordon 2016</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0015" title="HawkeyCJ , DubeLM , RountreeLV , LinnenPJ , LancasterJF , the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology1997;112:718-24. ">Hawkey 1997</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>). Overall, 4% (31/806) of 5‐ASA participants were withdrawn due to AEs compared to 5% (25/547) of placebo participants (RR 0.86, 95% CI 0.50 to 1.47; I² = 0%; <a href="./references#CD000544-fig-0008" title="">Analysis 1.6</a>). Common AEs leading to withdrawal include UC aggravation, diarrhea, headache, and paresthesia. See <a href="./full#CD000544-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD000544-sec-0057"> <h5 class="title">Withdrawals after study entry</h5> <p>Five studies (1074 participants) reported the proportion of participants excluded or withdrawn after entry (<a href="./references#CD000544-bbs2-0003" title="ArdizzoneS , PetrilloM , ImbesiV , CeruttiR , BollaniS , Bianchi PorroG . Is maintenance therapy always necessary for patients with ulcerative colitis?Alimentary Pharmacology and Therapeutics1999;13:373-9. ">Ardizzone 1999</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0026" title="LichtensteinGR , GordonGL , ZakkoS , MurthyU , SedghiS , PruittR , et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics2010;32(8):990-9. ">Lichtenstein 2010</a>; <a href="./references#CD000544-bbs2-0029" title="MinerP , HanauerS , RobinsonM , SchwartzJ , AroraS , Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences1995;40:296-304. MinerP , SchwartzJ , AoraS , RobinsonM , HanauerS , the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology1992;102:A666. ">Miner 1995</a>; <a href="./references#CD000544-bbs2-0044" title="WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences1993;38:1837-42. WrightJP , O'KeefeEA , CumingL , JaskiewiczK . Olsalazine in the maintenance of remission in patients with ulcerative colitis. Gastroenterology1992;102:A714. ">Wright 1993</a>). About 19% (113/592) of 5‐ASA participants were withdrawn or excluded after entry compared to 18% (89/482) of placebo participants at six to 12 months (RR 1.13, 95% CI 0.88 to 1.44; I² = 11%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0009" title="">Analysis 1.7</a>). See <a href="./full#CD000544-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> <section id="CD000544-sec-0058"> <h4 class="title">5‐Aminosalicylic acid versus sulfasalazine</h4> <p>Twelve trials (1655 participants) compared the efficacy of 5‐ASA and SASP (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0007" title="DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal1983;287:23-4. DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut1983;24(Suppl 10):A983. ">Dew 1983</a>; <a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>). Eight studies limited the dose of SASP to 2 g/day; one trial to 4 g/day; one trial had a mean dose of SASP of 2.7 g/day, which ranged from 2.4 g/day to 4.4 g/day (see <a href="./references#CD000544-sec-0107" title="">Characteristics of included studies</a>). See <a href="./full#CD000544-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD000544-sec-0059"> <h5 class="title">Endoscopic or clinical relapse</h5> <p>The outcome was defined as the failure to maintain clinical or endoscopic remission (withdrawals and relapses). About 48% (416/871) of 5‐ASA participants relapsed compared to 43% (336/784) of SASP participants at six to 18 months (RR 1.14, 95% CI 1.03 to 1.27; I² = 17%; high‐certainty evidence; <a href="./references#CD000544-fig-0010" title="">Analysis 2.1</a>). </p> <p>An analysis was done limited to those studies with endpoints at 12 months (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>), and there was no difference between the 5‐ASA and SASP groups (RR 1.10, 95% CI 0.98 to 1.23). Similarly, when the analysis was limited to studies that did not use olsalazine (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0007" title="DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal1983;287:23-4. DewMJ , HarriesAD , EvansN , EvansBK , RhodesJ . Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut1983;24(Suppl 10):A983. ">Dew 1983</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>), there was no difference between groups (RR 1.08, 95% CI 0.92 to 1.26; <a href="./references#CD000544-fig-0011" title="">Analysis 2.2</a>). </p> <p>Three trials involving Claversal had a pooled RR of 1.15 (95% CI 0.95 to 1.40) (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>). When the five trials involving olsalazine were pooled, the resulting odds ratio was 1.20 (95% CI 1.04 to 1.38), thus demonstrating that SASP was more effective than olsalazine for maintenance of remission (<a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>). See <a href="./full#CD000544-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD000544-sec-0060"> <h5 class="title">Adherence to medication regimen</h5> <p>None of the studies reported adherence to medication regimen.</p> </section> <section id="CD000544-sec-0061"> <h5 class="title">Adverse events</h5> <p>Seven studies (1138 participants) reported the proportion of participants who experienced at least one AE (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>). About 16% (98/608) of 5‐ASA participants and 16% (84/530) of SASP participants experienced at least one AE at six to 18 months (RR 1.07, 95% CI 0.82 to 1.40; I² = 41%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0012" title="">Analysis 2.3</a>). Three olsalazine trials including 634 participants that were homogeneous (I² = 0%) had a pooled odds ratio of 1.27 (95% CI 0.92 to 1.76) (<a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>). Commonly reported AEs in the SASP trials included: headache, anorexia or appetite loss, nausea, vomiting, abdominal pain, dyspepsia, excessive flatus, bloating, urticaria and rash. Five studies involving olsalazine (<a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>),and two studies involving Claversal (<a href="./references#CD000544-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. Clinical Controversies in Inflammatory Bowel Disease1987:170. ">Andreoli 1987</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>), reported diarrhea. See <a href="./full#CD000544-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD000544-sec-0062"> <h5 class="title">Serious adverse events</h5> <p>None of the studies reported SAEs.</p> </section> <section id="CD000544-sec-0063"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Ten studies (1585 participants) reported the proportion of participants withdrawn due to AEs (<a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>). About 7% (56/832) of 5‐ASA participants were withdrawn due to AEs compared to 5% (41/753) of SASP participants at six to 18 months (RR 1.27, 95% CI 0.87 to 1.87; I² = 0%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0013" title="">Analysis 2.4</a>). </p> <p>In five olsalazine trials including 906 participants, 9.2% of those receiving olsalazine and 6.2% of those receiving SASP were withdrawn because of AEs (RR 1.61, 95% CI, 1.01 to 2.56) (<a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>). The results from two Claversal trials including 422 participants were not different (RR 1.10, 95% CI, 0.48 to 2.54) (<a href="./references#CD000544-bbs2-0002" title="ArdizzoneS , PetrilloM , MolteniP , DesideriS , Bianchi PorroG . Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology1995;21:287-9. Bianchi PorroGB , ArdizzoneS , FasoliR , PetrilloM , DesideriS . Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut1989;30:A1467. ">Ardizzone 1995</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>). Nine studies involving 1497 participants reported the proportion of participants excluded or withdrawn after entry (excluding relapses) (<a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0028" title="McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BaronJH . Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut1986;27:A1271. McIntyrePB , RodriguesCA , Lennard-JonesJE , BarrisonIG , WalkerJG , BatonJH , et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics1988;2:237-43. ">McIntyre 1988</a>; <a href="./references#CD000544-bbs2-0030" title="MulderCJ , TytgatGN , WetermanIT , DekkerW , BlokP , SchrijverM , et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology1988;95:1449-53. MulderCJ , TytgatGN , WetermanIT . Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology1988;94(5 Part 2):A313. ">Mulder 1988</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>; <a href="./references#CD000544-bbs2-0037" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis. Gastroenterology2012;29(5):669-74. RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergLA . Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology1988;94:1383-9. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis. Gastroenterology1987;92:A1596. RileySA , ManiV , GoodmanMJ , TurnbergLA . A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC). Gut1987;28:1390. ">Riley 1988</a>; <a href="./references#CD000544-bbs2-0038" title="RutgeertsP . Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1989;3:183-91. ">Rutgeerts 1989</a>). See <a href="./full#CD000544-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD000544-sec-0064"> <h5 class="title">Withdrawals after study entry</h5> <p>About 19% (150/788) of 5‐ASA participants were excluded or withdrawn after entry compared to 15% (109/709) of SASP participants at six to 18 months (RR 1.30, 95% CI 1.04 to 1.63; <a href="./references#CD000544-fig-0014" title="">Analysis 2.5</a>). There was no significant heterogeneity detected (I² = 29%). Withdrawals or exclusions after entry were significantly higher in five olsalazine trials involving 906 participants (<a href="./references#CD000544-bbs2-0017" title="IrelandA , JewellDP . Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC). Gastroenterology1987;92:A1447. IrelandA , MasonCH , JewellDP . Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut1988;29:835-7. JewellDP , IrelandA . Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement1988;148:45-7. ">Ireland 1988a</a>; <a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>). About 17% of olsalazine participants were withdrawn or excluded after entry compared to 12% of SASP participants (RR 1.51, 95% CI 1.09 to 2.08). Common AEs leading to withdrawal include diarrhea, abdominal pain, indigestion, and rash. See <a href="./full#CD000544-tbl-0002">summary of findings Table 2</a>. </p> </section> </section> <section id="CD000544-sec-0065"> <h4 class="title">Once‐daily dosing versus conventional dosing</h4> <section id="CD000544-sec-0066"> <h5 class="title">Endoscopic or clinical relapse</h5> <p>Three trials (1871 participants) reported treatment outcomes in terms of failure to maintain clinical or endoscopic remission at six months (<a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>). About 19% (177/939) of once‐daily participants relapsed compared to 18% (172/932) of conventional‐dosing participants (RR 1.02, 95% CI 0.85 to 1.23; I² = 0%; <a href="./references#CD000544-fig-0015" title="">Analysis 3.1</a>). None of the subgroup comparisons by formulation showed any differences in efficacy between once‐daily dosing and conventional dosing. However, only two formulations were evaluated in this pooled analysis. </p> <p>Ten trials (3910 participants) reported treatment outcomes in terms of failure to maintain clinical or endoscopic remission at 12 to 13 months (<a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0021" title="KaneS , HoldermanW , JacquesP , MiodekT . Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence2008;2(2):253-8. ">Kane 2008b</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>; <a href="./references#CD000544-bbs2-0041" title="SuzukiY , lidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). About 37% (717/1939) of once‐daily participants relapsed compared to 39% (770/1971) of conventional‐dosing participants (RR 0.94, 95% CI 0.88 to 1.01; I² = 32%; high‐certainty evidence; <a href="./references#CD000544-fig-0016" title="">Analysis 3.2</a>). The subgroup comparison for Pentasa favored once‐daily dosing compared to conventional twice‐daily dosing (RR 0.75, 95% CI 0.60 to 0.93). None of the other subgroup comparisons (by formulation) showed any differences in efficacy between once‐daily dosing and conventional dosing. See <a href="./full#CD000544-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD000544-sec-0067"> <h5 class="title">Adherence to medication regimen</h5> <p>Nine trials (2306 participants) reported adherence with study medication at study endpoint (<a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a>; <a href="./references#CD000544-bbs2-0021" title="KaneS , HoldermanW , JacquesP , MiodekT . Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence2008;2(2):253-8. ">Kane 2008b</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). Overall, 9% (106/1152) of participants in the once‐daily group failed to adhere to their medication regimen compared to 7% (84/1154) of participants in the conventional‐dosing group (RR 1.18, 95% CI 0.72 to 1.93; I² = 57%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0017" title="">Analysis 3.3</a>) (6 months for <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a>, 13 months for <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>, and 12 months for the other studies in the pooled analysis). The heterogeneity appeared to be a result of the inclusion of two specific trials (<a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>). <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a> reported a higher compliance rate of 99.6% in the twice‐daily dosing group compared to 93.3% in the once‐daily group. <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a> reported a higher compliance rate of 97.1% in the once‐daily dosing group compared to 85.5% in the three times‐daily dosing group. To investigate if these studies were the source of the heterogeneity, we repeated the analysis excluding these trials. The pooled analysis of the ITT population now included seven studies and 1642 participants (<a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a>; <a href="./references#CD000544-bbs2-0021" title="KaneS , HoldermanW , JacquesP , MiodekT . Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence2008;2(2):253-8. ">Kane 2008b</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). Overall, 11% (88/830) of participants in the once‐daily group failed to adhere to their medication regimen compared to 8% (67/812) of participants in the conventional‐dosing group (RR 1.22, 95% CI 0.92 to 1.62; I² = 0%; <a href="./references#CD000544-fig-0018" title="">Analysis 3.4</a>). See <a href="./full#CD000544-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD000544-sec-0068"> <h5 class="title">Adverse events</h5> <p>Eight studies (3497 participants) reported the proportion of participants who experienced at least one AE (<a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0041" title="SuzukiY , lidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). About 48% of once‐daily (835/1739) and 49% (862/1758) of conventional‐dosing participants experienced at least one AE at six to 13 months (RR 0.98, 95% CI 0.92 to 1.04; I² = 0%; high‐certainty evidence; <a href="./references#CD000544-fig-0019" title="">Analysis 3.5</a>). The most common AEs reported in the trials assessing once‐daily dosing included flatulence, dyspepsia, abdominal pain, nausea, diarrhea, headache, nasopharyngitis, inflammation of the upper respiratory tract, gastroenteritis, dental caries, and worsening of UC. See <a href="./full#CD000544-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD000544-sec-0069"> <h5 class="title">Serious adverse events</h5> <p>Seven studies (3196 participants) reported the proportion of participants who experienced at least one SAE (<a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0033" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ParkSK , ParkSH , EunCS , SeoGS , ImJP , KimTO , et al. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intestinal Research2019;17(3):349-56. ">Park 2019</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0041" title="SuzukiY , lidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>). About 3% (41/1587) of participants in the once‐daily group experienced at least one SAE compared to 2% (35/1609) of participants in the conventional‐dosing group at six to 13 months (RR 1.20, 95% CI 0.77 to 1.87; I² = 0%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0020" title="">Analysis 3.6</a>). Reported SAEs included UC aggravation, acute pancreatitis, anal fistula, pneumonia, melena, nephrolithiasis, and hypersensitivity pneumonitis. See <a href="./full#CD000544-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD000544-sec-0070"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Eight studies (4340 participants) reported the proportion of participants who were withdrawn due to AEs (<a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>; <a href="./references#CD000544-bbs2-0041" title="SuzukiY , lidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). Withdrawals due to AEs were 2% (36/2160) in the once‐daily group compared to 1% (31/2180) in the conventional‐dosing group at six to 13 months (RR 1.18, 95% CI 0.74 to 1.89; I² = 15%; very low‐certainty evidence; <a href="./references#CD000544-fig-0021" title="">Analysis 3.7</a>). See <a href="./full#CD000544-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD000544-sec-0071"> <h5 class="title">Withdrawals after study entry</h5> <p>Seven studies (3737 participants) reported the proportion of participants who were excluded or withdrawn after entry (<a href="./references#CD000544-bbs2-0005" title="D'HaensG , SandbornWJ , BarrettK , HodgsonI , StreckP . Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology2012;107(7):1064-77. ">D'Haens 2012</a>; <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>; <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>; <a href="./references#CD000544-bbs2-0043" title="WatanabeM , HanaiH , NishinoH , YokoyamaT , TeradaT , SuzukiY . Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases2013;19(8):1681-90. ">Watanabe 2013</a>). Approximately 15% (276/1858) of once‐daily and 15% of conventional‐dosing (281/1879) participants were excluded or withdrawn after entry at six to 13 months (RR 0.99, 95% CI 0.85 to 1.15; I² = 0%; high‐certainty evidence; <a href="./references#CD000544-fig-0022" title="">Analysis 3.8</a>). Common AEs leading to withdrawal include UC aggravation, flatulence, nausea, and abdominal distension. See <a href="./full#CD000544-tbl-0003">summary of findings Table 3</a>. </p> </section> </section> <section id="CD000544-sec-0072"> <h4 class="title">5‐Aminosalicylic acid versus comparator 5‐aminosalicylic acid formulation</h4> <section id="CD000544-sec-0073"> <h5 class="title">Endoscopic or clinical relapse</h5> <p>Six studies (707 participants) reported treatment outcomes in terms of the failure to maintain clinical or endoscopic remission at six to 18 months (<a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0018" title="ItoH , IidaM , MatsumotoT , SuzukiY , AidaY , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1575-82. ">Ito 2010</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>). The overall pooled RR showed no difference in relapse between various formulations of 5‐ASA (including balsalazide, Pentasa, and olsalazine) and comparator formulations of 5‐ASA (including Asacol and Salofalk). About 44% (158/358) of participants in the 5‐ASA group relapsed compared to 41% (142/349) of participants in the 5‐ASA comparator group. The pooled RR of relapse was 1.08 using a fixed‐effect model (95% CI 0.91 to 1.28; I² = 31%; <a href="./references#CD000544-fig-0023" title="">Analysis 4.1</a>). The GRADE analysis indicated that the overall certainty of the evidence for the primary outcome (failure to maintain clinical or endoscopic remission) was low due to sparse data (300 events) and a high risk of bias (lack of blinding) in two studies in the pooled analysis. See <a href="./full#CD000544-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD000544-sec-0074"> <h5 class="title">Adherence to medication regimen</h5> <p>None of the studies reported adherence to medication regimen.</p> </section> <section id="CD000544-sec-0075"> <h5 class="title">Adverse events</h5> <p>Four studies (357 participants) reported the proportion of participants who experienced at least one AE between various formulations of 5‐ASA (including balsalazide, Pentasa, and olsalazine) and comparator formulations of 5‐ASA (including Asaco and Salofalk) (<a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0018" title="ItoH , IidaM , MatsumotoT , SuzukiY , AidaY , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1575-82. ">Ito 2010</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>). About 64% (116/182) of participants in the 5‐ASA group experienced at least one AE compared to 69% (120/175) of participants in the 5‐ASA comparator group at six to 12 months (RR 0.94, 95% CI 0.83 to 1.07; I² = 8%; low‐certainty evidence; <a href="./references#CD000544-fig-0024" title="">Analysis 4.2</a>). The most common AEs reported in these trials included dyspepsia, abdominal pain, nausea, distension, diarrhea, headache, nasopharyngitis or respiratory infections, influenza‐like disorder, and rash. See <a href="./full#CD000544-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD000544-sec-0076"> <h5 class="title">Serious adverse events</h5> <p>One study (95 participants) reported on the proportion of participants who experienced at least one SAE (<a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>). About 6% (3/49) of participants in the 5‐ASA group experienced at least one SAE compared to 11% (5/46) of participants in the 5‐ASA comparator group (RR 0.56, 95% CI 0.14 to 2.22; <a href="./references#CD000544-fig-0025" title="">Analysis 4.3</a>). Commonly reported SAEs included a urinary tract infection, a severe complication of UC, cardiac arrest, ischemic heart disease, fracture of the scaphoid, and a spigelian hernia. See <a href="./full#CD000544-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD000544-sec-0077"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Five studies (457 participants) reported the proportion of participants who were withdrawn due to AEs (<a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0018" title="ItoH , IidaM , MatsumotoT , SuzukiY , AidaY , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1575-82. ">Ito 2010</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>). About 6% (13/232) of participants in the 5‐ASA group were withdrawn due to AEs compared to 4% (10/225) of participants in the 5‐ASA comparator group at 12 months (RR 1.25, 95% CI 0.56 to 2.78; I² = 0%; very low‐certainty evidence; <a href="./references#CD000544-fig-0026" title="">Analysis 4.4</a>). Common AEs leading to withdrawal include headache, lethargy, hypertension, malaise, and abdominal pain. See <a href="./full#CD000544-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD000544-sec-0078"> <h5 class="title">Withdrawals after study entry</h5> <p>Five studies (457 participants) reported the proportion of participants who were excluded or withdrawn after entry between various formulations of 5‐ASA (including balsalazide, Pentasa, and olsalazine) and comparator formulations of 5‐ASA (including Asacol and Salofalk) (<a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>; <a href="./references#CD000544-bbs2-0013" title="GreenJR , GibsonJA , KerrGD , SwarbrickET , LoboAJ , HoldsworthCD , et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics1998;12:1207-16. ">Green 1998</a>; <a href="./references#CD000544-bbs2-0018" title="ItoH , IidaM , MatsumotoT , SuzukiY , AidaY , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1575-82. ">Ito 2010</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>). About 28% (64/232) of participants in the 5‐ASA group were excluded or withdrawn after entry compared to 22% (50/225) of participants in the 5‐ASA comparator group at six to 12 months (RR 1.23, 95% CI 0.90 to 1.70; I² = 0%; moderate‐certainty evidence; <a href="./references#CD000544-fig-0027" title="">Analysis 4.5</a>). See <a href="./full#CD000544-tbl-0004">summary of findings Table 4</a>. </p> </section> </section> <section id="CD000544-sec-0079"> <h4 class="title">5‐Aminosalicylic acid dose ranging</h4> <p>Several randomized trials looked at dose‐ranging for various formulations of 5‐ASA including Asacol, balsalazide, olsalazine, Salofalk, and Pentasa. </p> <section id="CD000544-sec-0080"> <h5 class="title">Endoscopic or clinical relapse</h5> <p>Four studies examined the efficacy of various doses of Asacol for maintenance of clinical or endoscopic remission (<a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>; <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a>). <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a> found no difference in efficacy between Asacol 4.8 g/day compared to 2.4 g/day. About 29% (16/56) of participants in the Asacol 4.8 g/day group relapsed compared to 36% (20/56) in the 2.4 g/day group (RR 0.80, 95% CI 0.46 to 1.38; 112 participants; very low‐certainty evidence; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a> found no difference in efficacy between Asacol 3.2 g/day compared to 2 g/day. About 51% (70/138) of participants in the Asacol 3.2 g/day group relapsed compared to 48% (59/124) of participants in the 2 g/day group (RR 1.07, 95% CI 0.83 to 1.37; 262 participants; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a> found no difference in efficacy between Asacol 2.4 g/day compared to 1.2 g/day. About 70% (56/80) of participants in the Asacol 2.4 g/day group relapsed compared to 74% (56/76) in the 1.2 g/day group (RR 0.95, 95% CI 0.78 to 1.16; 156 participants; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a> found no difference in efficacy between Asacol 1.6 g/day compared to 0.8 g/day. About 56% (49/87) of participants relapsed in the 1.6 g/day group compared to 56% (50/90) of participants in the 0.8 g/day group (RR 1.01, 95% CI 0.78 to 1.32; 177 participants; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). </p> <p>Three studies examined the efficacy of various doses of balsalazide (3 g/day to 6 g/day) for maintenance of clinical or endoscopic remission (<a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a>; <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>). Two of these studies compared balsalazide 6 g/day to 3 g/day (<a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>). About 23% (24/104) of participants in the 6 g/day group relapsed compared to 33% (37/112) of participants in the 3 g/day group (RR 0.76, 95% CI 0.21 to 2.79; 216 participants). However, these results should be interpreted with caution as there was significant heterogeneity (I² = 86%). <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a> compared balsalazide 4 g/day to 2 g/day and found a difference favoring the 4 g/day dose group. About 37% (25/68) of participants in the 4 g/day group relapsed compared to 55% (36/65) of participants in the 2 g/day group (RR 0.66, 95% CI 0.45 to 0.97; 133 participants; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). </p> <p><a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a> found no significant difference in efficacy between olsalazine 2 g/day and 1 g/day. About 40% of participants in both dose groups relapsed (RR 1.01, 95% CI 0.66 to 1.54; 127 participants; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a> found a difference between Salofalk granules 3 g/day and 1.5 g/day. About 25% (55/217) of participants in the Salofalk 3 g/day group relapsed compared to 39% (83/212) of participants in the 1.5 g/day group (RR 0.65, 95% CI 0.49 to 0.86; 429 participants; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). <a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a> found no significant difference in efficacy between Pentasa 3.0 g/day and 1.5 g/day. About 28% (23/82) of participants in the 3.0 g/day group relapsed compared to 38% (33/87) in the 1.5 g/day group (RR 0.74, 95% CI 0.48 to 1.15; 169 participants; <a href="./references#CD000544-fig-0028" title="">Analysis 5.1</a>). </p> </section> <section id="CD000544-sec-0081"> <h5 class="title">Adherence to medication regimen</h5> <p>None of the studies reported adherence to medication regimen.</p> </section> <section id="CD000544-sec-0082"> <h5 class="title">Adverse events</h5> <p>Five dose‐ranging studies (977 participants) reported the proportion of participants who experienced at least one AE at six to 12 months (<a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>; <a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>). <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a> found a difference in the proportion of participants who experienced at least one AE between Salofalk 3 g/day and 1.5 g/day both dosed once daily. About 41% (89/217) of participants in the 3 g/day group experienced at least one AE compared to 55% (117/212) of participants in the 1.5 g/day group (RR 0.74, 95% CI 0.61 to 0.91; 429 participants; <a href="./references#CD000544-fig-0029" title="">Analysis 5.2</a>). <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a> found a difference in the proportion of participants who experienced at least one AE between Asacol 1.6 g/day and 0.8 g/day. About 41% (36/87) of participants in the Asacol 1.6 g/day group experienced at least one AE compared to 22% (20/90) of participants in the 0.8 g/day group (RR 1.86; 95% CI 1.18 to 2.95; 177 participants; <a href="./references#CD000544-fig-0029" title="">Analysis 5.2</a>). There were no differences in the incidence of AEs between Asacol 2.4 g/day and 1.2 g/day (RR 2.85, 95% CI 0.12 to 68.95; 156 participants), balsalazide 6.0 g/day and 3.0 g/day (RR 1.40, 95% CI 0.88 to 2.24; 88 participants; <a href="./references#CD000544-fig-0029" title="">Analysis 5.2</a>), and olsalazine 2.0 g/day and 1.0 g/day (RR 1.37, 95% CI 0.94 to 1.99; 127 participants; <a href="./references#CD000544-fig-0029" title="">Analysis 5.2</a>). Common AEs include headaches, abdominal pain, and diarrhea. </p> </section> <section id="CD000544-sec-0083"> <h5 class="title">Serious adverse events</h5> <p>Two studies (606 participants) reported on the incidence of SAEs between the high‐dose and low‐dose groups (<a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>). About 3% (9/304) of participants in the high‐dose group compared to 3% (8/302) of participants in the low‐dose 5‐ASA group experienced an SAE at six 12 months (RR 1.11, 95% CI 0.43 to 2.82; low‐certainty evidence; <a href="./references#CD000544-fig-0030" title="">Analysis 5.3</a>). The trials did not report the specific SAEs. </p> </section> <section id="CD000544-sec-0084"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Seven dose‐ranging studies (1260 participants) reported the proportion of participants who were withdrawn due to AEs at six to 12 months (<a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a>; <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a>; <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>). There were no differences in withdrawal due to AEs between Asacol 2.4 g/day and 1.2 g/day (RR 2.85, 95% CI 0.12 to 68.95; 1 study, 156 participants; <a href="./references#CD000544-fig-0031" title="">Analysis 5.4</a>); Asacol 1.6 g/day and 0.8 g/day (RR 0.34, 95% CI 0.04 to 3.25; 1 study, 177 participants; <a href="./references#CD000544-fig-0031" title="">Analysis 5.4</a>); balsalazide 6.0 g/day and 3.0 g/day (RR 0.59, 95% CI 0.21 to 1.70; 2 studies, 196 participants; <a href="./references#CD000544-fig-0031" title="">Analysis 5.4</a>); balsalazide 4.0 g/day and 2.0 g/day (RR 1.43, 95% CI 0.54 to 3.80; 1 study, 133 participants; <a href="./references#CD000544-fig-0031" title="">Analysis 5.4</a>); and Pentasa 3.0 g/day and 1.5 g/day (RR 1.06, 95% CI 0.07 to 16.69; 1 study, 169 participants; <a href="./references#CD000544-fig-0031" title="">Analysis 5.4</a>). Common AEs leading to withdrawal included headache, hypertension, malaise, and abdominal pain. </p> </section> <section id="CD000544-sec-0085"> <h5 class="title">Withdrawals after study entry</h5> <p>Eight dose‐ranging studies (1387 participants) reported the proportion of participants who were excluded or withdraw after entry at six to 12 months (<a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a>; <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a>; <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a>; <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a>; <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a>; <a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>). There was a difference between balsalazide 6.0 g/day and 3.0 g/day (RR 0.47, 95% CI 0.26 to 0.84; 2 studies, 196 participants; <a href="./references#CD000544-fig-0032" title="">Analysis 5.5</a>) and between Salofalk 3 g/day and 1.5 g/day (RR 0.66, 95% CI 0.46 to 0.93; 1 study, 429 participants; <a href="./references#CD000544-fig-0032" title="">Analysis 5.5</a>). There were no significant differences in exclusions or withdrawals after entry between Asacol 2.4 g/day and 1.2 g/day (RR 0.95, 95% CI 0.38 to 2.40; 1 study, 156 participants; <a href="./references#CD000544-fig-0032" title="">Analysis 5.5</a>); Asacol 1.6 g/day and 0.8 g/day (RR 1.23, 95% CI 0.80 to 1.90; 1 study, 177 participants; <a href="./references#CD000544-fig-0032" title="">Analysis 5.5</a>); balsalazide 4.0 g/day and 2.0 g/day (RR 1.27, 95% CI 0.77 to 2.12; 1 study, 133 participants; <a href="./references#CD000544-fig-0032" title="">Analysis 5.5</a>); olsalazine 2.0 g/day and 1.0 g/day (RR 1.75, 95% CI 0.83 to 3.70; 1 study, 127 participants; <a href="./references#CD000544-fig-0032" title="">Analysis 5.5</a>); and Pentasa 3.0 g/day and 1.5 g/day (RR 0.83, 95% CI 0.44 to 1.55; 1 study, 169 participants; <a href="./references#CD000544-fig-0032" title="">Analysis 5.5</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000544-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000544-sec-0086"></div> <section id="CD000544-sec-0087"> <h3 class="title" id="CD000544-sec-0087">Summary of main results</h3> <p>This updated systematic review largely confirms the results of previous meta‐analyses (<a href="./references#CD000544-bbs2-0138" title="FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub3]">Feagan 2012</a>; <a href="./references#CD000544-bbs2-0139" title="SutherlandLR , MayGR , ShafferEA . Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine1993;118:540-9.">Sutherland 1993</a>; <a href="./references#CD000544-bbs2-0140" title="SutherlandLR , RothDE , BeckPL . Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases1997;3:65-78.">Sutherland 1997</a>; <a href="./references#CD000544-bbs2-0141" title="SutherlandLR , MacDonaldJK . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub2]">Sutherland 2006</a>; <a href="./references#CD000544-bbs2-0142" title="WangY , ParkerCE , FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub4]">Wang 2016</a>). This updated review includes 44 studies and 9967 participants which greatly increases statistical power. The results of this systematic review provide strong evidence that point towards a number of conclusions. </p> <p>The effectiveness of oral 5‐ASA preparations for maintenance of remission in quiescent UC was confirmed. Oral 5‐ASA is superior to placebo for maintenance of remission in UC. There may be a trend towards greater efficacy with higher doses of 5‐ASA with a benefit for the 1 g/day to 1.9 g/day and the 2 g/day or greater dosage groups. </p> <p>An interesting result was that SASP had a modest benefit over 5‐ASA. When the pooled analysis was limited to trials with endpoints at 12 months, the difference was no longer significant. Nevertheless, certain limitations may have resulted from having combined all trials regardless of whether relapse was defined in terms of clinical or endoscopic criteria. It is possible that the 'superiority' of SASP over 5‐ASA reflects the ITT analysis that was employed. This technique considers all participants who received the medication and penalizes medications with high dropout rates (e.g. olsalazine). A per protocol analysis, which includes those participants who are compliant and who tolerate the medication, might not support a 'superiority' claim. </p> <p>When data for maintenance therapy were subgrouped according to the specific 5‐ASA preparation, olsalazine was significantly inferior to SASP. Firm conclusions regarding other preparations, which have generally been subject to less‐rigorous clinical evaluation, could not be surmised. In the case of olsalazine, it appeared that the reduced efficacy was influenced by the significantly higher proportions of withdrawals due to AEs and total exclusions or withdrawals of participants receiving olsalazine compared to those receiving SASP. In fact, if the analysis of efficacy was restricted to relapses as treatment failures, excluding withdrawals for other reasons, there was no significant difference between olsalazine and SASP (data not shown). The difference may also be related to a misclassification bias in which participants who developed diarrhea were falsely classified as treatment relapses rather than having experienced AEs. </p> <p>The overall superiority of SASP over 5‐ASA for maintenance therapy may also be attributable to certain pharmacological properties of SASP, including potential therapeutic effects of the sulfapyridine moiety, that are not observed with other 5‐ASA delivery systems. The mechanisms of action of SASP and its metabolites have been reviewed by <a href="./references#CD000544-bbs2-0099" title="GreenfieldSM , PunchardNA , TeareJP , ThompsonRP . Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics1993;7:369-83.">Greenfield 1993</a>. </p> <p>It was apparent that the newer 5‐ASA preparations had adverse effects in several participants. However, the incidence of AEs, SAEs, and withdrawals due to the 5‐ASA formulations did not significantly differ from that associated with placebo. There was also no apparent difference between the number of AEs caused by SASP and 5‐ASA. It should be noted that there may have been a bias in favor of SASP since many of the studies involved participants who were known to have tolerated SASP in the past. This may have minimized SASP‐related AEs in these trials. </p> <p>In contrast to these results, olsalazine was associated with a significantly higher proportion of withdrawals due to AEs relative to SASP. The most common AE attributed to olsalazine was diarrhea, an effect previously observed in approximately 10% of participants receiving the drug (<a href="./references#CD000544-bbs2-0105" title="IrelandA , JewellDP . Olsalazine in patients intolerant of sulfasalazine. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):101-3.">Ireland 1988b</a>). It has been suggested that protocol alterations may reduce withdrawal rates in future trials since it has been reported that encouraging participants to take olsalazine with meals appears to reduce the incidence of diarrhea to approximately 3% of participants (<a href="./references#CD000544-bbs2-0106" title="JarnerotG . Withdrawal rates because of diarrhoea in Dipentum-treated patients with ulcerative colitis are low when Dipentum is taken with food and dose titrated [abstract]. Gastroenterology1996;110:A932.">Jarnerot 1996</a>). However, four of the five olsalazine‐SASP trials reported that such recommendations were in fact made (<a href="./references#CD000544-bbs2-0022" title="KiilerichS , LadefogedK , RannemT , RanlovP . Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology1991;100(5 Part 2):A220. KiilerichS , LadefogedK , RannemT , RanlovPJ . Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut1992;33:252-5. ">Kiilerich 1992</a>; <a href="./references#CD000544-bbs2-0023" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , JudmaierG , KayassehL , StoleM , TheuerD , ScheurlenC , et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7:391-6. KruisW , JudmaierG , KayassehL , StolteM , ScheurlenC , HentschelE , et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis. Gastroenterology1992;102:A649. KruisW , StolteM . A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology1991;100(5 Part 2):A222. ">Kruis 1995</a>; <a href="./references#CD000544-bbs2-0031" title="NilssonA , DanielssonA , LofbergR , BennoP , BergmanL , FausaO , et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology1995;90:381-7. ">Nilsson 1995</a>; <a href="./references#CD000544-bbs2-0036" title="RijkMC , LierHJ , TongersonJH . Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology1992;87:438-42. RijkMC , vanTongersenJH . The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology1991;100(5 Part 2):A243. ">Rijk 1992</a>). </p> <p>High‐certainty evidence suggests that 5‐ASA administered once daily is as effective as conventional dosing (twice or three times daily) for maintenance of remission over six‐ and 12‐month periods in participants with quiescent UC. With the exception of Pentasa, subgroup analyses by drug formulation showed no significant differences in efficacy between once‐daily and conventional dosing for maintenance of remission. <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a> found that 2 g of Pentasa dosed once daily was superior to 1 g Pentasa dosed twice daily for maintenance of remission at 12 months. The other Pentasa study found no difference between once‐daily and conventional dosing for maintenance of remission. A plausible biological explanation for the <a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a> finding is not readily apparent to us. </p> <p>The results of this meta‐analysis suggest that there is no difference in safety between once‐daily and conventional‐dose 5‐ASA. There were no differences between once‐daily and conventional‐dose 5‐ASA for safety outcomes including the overall incidence of AEs, SAEs, or withdrawal from treatment due to an AE. In keeping with the well‐established safety profile of 5‐ASA, most of the AEs reported in the studies assessing once‐daily dosing were mild to moderate in intensity. Common AEs included gastrointestinal symptoms (e.g. flatulence, abdominal pain, nausea, and diarrhea), headache, and worsening UC. </p> <p>Important patient preference and adherence differences may exist between dosing regimens. In the study that measured participant preference, most participants preferred once‐daily dosing to conventional dosing (<a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>). Although it is generally believed that administration of fewer pills and less‐frequent dosing improves both efficacy and adherence, we could not demonstrate the superiority of once‐daily dosing for either of these outcomes. This result suggests that patient adherence may not be enhanced by once‐daily dosing in the clinical trial setting. Several possible explanations exist for these observations, however the most plausible one concerns the unique aspects of the clinical trial environment. It is noteworthy that adherence with medication was remarkably high in the studies that measured this outcome (<a href="./references#CD000544-bbs2-0008" title="BokemeyerB , HommesD , GillI , BrobergP , DignassA . Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis2012;6(4):476-82. DignassA , BokemeyerB , MrossM , Oudkerk PoolM . Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis2013;7:S153-4. DignassA , BokemeyerB , StijnenT , KlugmannT , OudkerkM , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. In: Canadian Journal of Gastroenterology. Vol. 23. 2009. DignassA , BokemeyerB , StijnenT , TanT , BornerN , Oudkerk PoolM , et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology2009;23:S73. DignassA , StijnenT , MrossMR , VermeireS , VeermanH , BhattA . Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology2007;132(4 Suppl 1):A502-3. DignassA , VermeireS , AdamekH , BefritsR , BokemeyerB , BörnerN , et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. In: UEGW – Abstract Database. 2007:OP-G-378. DignassAU , BokemeyerB , AdamekH , MrossM , Vinter-JensenL , BörnerN , et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(7):762-9. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology2008;134(4 Suppl 1):A494. DignassAU , BokemeyerB , AdamekHE , MrossMR , Vinter-JensenL , BoernerN , et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology2008;134(4 Suppl 1):A495-6. DignassAU , BokemeyerB , StijnenT , VeermanH . Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology2009;136(5 Suppl 1):A685. DignassAU , MulsV , SilvennoinenJ , PoolMO , BefritsR , BrobergP , et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology2010;1:S520. VermeireS , BefritsR , BokemeyerB , GillI , HommesDW , BrobergP , et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology2010;1:S522. ">Dignass 2009a</a>; <a href="./references#CD000544-bbs2-0016" title="HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut2011;60:A37-8. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology2011;140(5 Suppl 1):S65. HawthorneAB , StensonR , GillespieD , SwarbrickET , DharA , KapurKC , et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease2012;18(10):1885-93. ">Hawthorne 2012</a>; <a href="./references#CD000544-bbs2-0019" title="KammMA , ColombelJ , KornbluthA , DieboldR , BarrettK , KarlstadtRG , et al. A randomized comparison of once- versus twice-daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A510. KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut2008;57(7):893-902. KammMA , SchreiberS , ButlerT , BarrettK , StephensonD , JosephRE . Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. In: UEGW Abstract Database. 2006:MON-G-230. RubinD , DubinskyM , PanaccioneR , SiegelC , BinionD , KaneS , et al. Ulcerative colitis: patients’ perceptions compared with other chronic diseases. Inflammatory Bowel Diseases2008;14(S1):S22. SandbornW , KammM , LichtensteinG , BarrettK , JosephR . MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2008;14(S1):S24. ">Kamm 2008</a>; <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a>; <a href="./references#CD000544-bbs2-0035" title="KohnA , PranteraC , CaprilliR , CampieriM , CottoneM , PalloneF , et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology2009;136(5 Suppl 1):390. PranteraC , KohnA , CampieriM , CaprilliR , CottoneM , PalloneF , et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics2009;30(9):908-18. ">Prantera 2009</a>). The pooled adherence rate for the maintenance of remission studies was 86% for the once‐daily dosing group compared to 89% for the conventional‐dosing group. These rates likely reflect the highly supervised environment in which the studies were conducted. Adherence with medication in clinical trials is generally greater than in clinical practice since participants are highly selected volunteers who are more likely, in general, to be adherent with drug regimens (<a href="./references#CD000544-bbs2-0086" title="AndradeSE , WalkerAM , GottliebLK , HollenbergNK , TestaMA , SaperiaGM , et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings?New England Journal of Medicine1995;332(17):1125-31.">Andrade 1995</a>; <a href="./references#CD000544-bbs2-0107" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000544-bbs2-0109" title="KaneSV . Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(5):577-85.">Kane 2006</a>; <a href="./references#CD000544-bbs2-0110" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008a</a>). In addition, adherence is continuously reinforced during the clinical trial process. Thus, it may be difficult to detect differences in adherence between once‐daily and multiple‐dose regimens in this setting. </p> <p>Accordingly, a need exists to compare dosing regimens in large‐scale community‐based studies. In this regard, reported adherence rates in community‐based studies range from 40% to 60% and are especially poor among patients in remission (<a href="./references#CD000544-bbs2-0107" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000544-bbs2-0108" title="KaneS , HuoD , AikensJ , HanauerS . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine2003;114(1):39-43.">Kane 2003a</a>; <a href="./references#CD000544-bbs2-0113" title="LevyRL , FeldAD . Increasing patient adherence to gastroenterology treatment and prevention regimens. American Journal of Gastroenterology1999;94(7):1733-42.">Levy 1999</a>; <a href="./references#CD000544-bbs2-0132" title="ShaleMJ , RileySA . Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2003;18(2):191-8.">Shale 2003</a>). However, whether once‐daily dosing regimens improve adherence in the community remains unknown. Although <a href="./references#CD000544-bbs2-0020" title="KaneS , HuoD , MagnantiK . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology2003;1(3):170-3. ">Kane 2003b</a> demonstrated significantly higher adherence among people receiving once‐daily dosing compared to conventional dosing at three months, there were no significant differences at six months. This time‐dependent effect has been observed in a larger study (<a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>). <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a> found significantly higher adherence among participants using once‐daily dosing compared to conventional dosing at three months. However, there was no significant difference in adherence at six and 12 months (<a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a>). </p> <p>Experience from other indications suggest that factors other than the dosing regimen are important for long‐term compliance (<a href="./references#CD000544-bbs2-0089" title="BrixnerD , MagowanS , AccorttN . Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. Academy of Managed Care Pharmacy 19th Annual Meeting; 2007 Apr 10–13; San Diego (CA), 2007.">Brixner 2007</a>; <a href="./references#CD000544-bbs2-0110" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008a</a>). Long‐term observations in people with UC as well as in other conditions indicate that patients' and physicians' behaviors play a dominant role in adherence (<a href="./references#CD000544-bbs2-0088" title="Beaulieu DB SchwartzDA . Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes CME. MedScape CME Gastroenterology Posted 22 December 2009.">Beaulieu 2009</a>; <a href="./references#CD000544-bbs2-0115" title="MagowanS , KaneS , LangeJL . 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens. American Journal of Gastroenterology2006;101:S447.">Magowan 2006</a>). The patient–physician relationship should reinforce adherence through education, open communication, and mutual agreement regarding the value of treatment (<a href="./references#CD000544-bbs2-0110" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008a</a>). To ensure continued adherence in a community‐based setting, <a href="./references#CD000544-bbs2-0040" title="SandbornW , KaneS , KorzenikJ , LashnerB , LeightonJ , MahadevanU , et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases2009;15:S15. SandbornWJ , KorzenikJ , LashnerB , LeightonJA , MahadevanU , MarionJF , et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology2010;138(4):1286-96. ">Sandborn 2010</a> have emphasized the importance of healthcare providers evaluating and reinforcing compliance with patients after three months of maintenance therapy. </p> <p>There may be little or no difference in efficacy between the various formulations of oral 5‐ASA. The overall pooled RR (6 studies, 707 participants) showed no difference in relapse between various formulations of 5‐ASA (including balsalazide, Pentasa, and olsalazine) and comparator formulations of 5‐ASA (including Asacol and Salofalk). However, a GRADE analysis indicated that the overall certainty of the evidence for the primary outcome (failure to maintain clinical or endoscopic remission at 12 months) was low due to a high risk of bias (single blind and open‐label) in three studies in the pooled analysis and sparse data (see <a href="./full#CD000544-tbl-0004">summary of findings Table 4</a>). However, the open‐label study (<a href="./references#CD000544-bbs2-0027" title="MahmudN , O'TooleD , O'HareN , FreynePJ , WeirDG , KelleherD . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics2002;16(2):207-15. ">Mahmud 2002</a>), and one of the single‐blind studies (<a href="./references#CD000544-bbs2-0004" title="CourtneyMG , NunesDP , BerginCF , O'DriscollM , TrimbleV , KeelingPW , et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet1992;339:1279-81. CourtneyMG , NunesDP , BerginCF . Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology1990;98(5 Part 2):A165. ">Courtney 1992</a>), included endoscopy as an endpoint, which may provide some protection against performance and detection bias. </p> <p>Pharmacokinetic studies suggest that systemic exposure to 5‐ASA is similar for all oral 5‐ASA formulations and 5‐ASA prodrugs (<a href="./references#CD000544-bbs2-0126" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>; <a href="./references#CD000544-bbs2-0127" title="SandbornWJ , HanauerSB , BuchA . Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. Asacol and Colazal. American Journal of Gastroenterology2002;97:S263.">Sandborn 2002b</a>; <a href="./references#CD000544-bbs2-0128" title="SandbornWJ , HanauerSB . The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: a systematic review. American Journal of Gastroenterology2002;97:S269.">Sandborn 2002c</a>; <a href="./references#CD000544-bbs2-0129" title="SandbornWJ , HanauerSB . Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology and Therapeutics2003;17(1):29-42.">Sandborn 2003</a>). The excretory function of the kidneys (as measured by the glomerular filtration rate) does not change during maintenance therapy with oral 5‐ASA or olsalazine, and nephrotoxicity is rare for Pentasa or Asacol, suggesting that the systemic exposure to 5‐ASA that occurs for doses used in clinical practice is safe for all drugs in this class (<a href="./references#CD000544-bbs2-0126" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>). With the exception of olsalazine‐related diarrhea, there appears to be no difference in safety between the various formulations of oral 5‐ASA. The overall pooled RRs showed no differences in the incidence of AEs, SAEs, withdrawal due to AEs, or exclusions or withdrawals after entry. These results suggest that there may be little or no difference in safety across oral 5‐ASA formulations. Treatment with SASP and olsalazine may not be preferable due to the high frequency of AEs. When deciding which 5‐ASA formulations to use, physicians and patients should consider dose‐response data, adherence issues related to dose forms (size of dose form and total number of pills or capsules per day), and price (<a href="./references#CD000544-bbs2-0126" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>). </p> <p>Few dose‐ranging maintenance studies were performed, which limits the conclusions that can be drawn. <a href="./references#CD000544-bbs2-0014" title="HanauerS , PowersB , RobinsonM , MayleJ , ElsonC . Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology1994;106:A696. HanauerSB , SninskyCA , RobinsonM , PowersBJ , McHattieJD , MayleJE , et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine1996;124:204-11. ">Hanauer 1996</a> compared Asacol at a dosage of 1.6 g/day to 0.8 g/day and found no difference in relapse rates between groups. <a href="./references#CD000544-bbs2-0006" title="DeventerSJ , HommesDW , Roskam-MulMD , DekkerW , GasthuisK , WetzelsA , et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology2001;120(5 Suppl 1):A454. ">Deventer 2001</a> compared 3.2 g/day to 2 g/day and found no difference in relapse rates between groups. <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a> compared Asacol at a dosage of 2.4 g/day to 1.2 g/day and found no difference in relapse rates between groups. However, participants in the higher‐dosage group remained in remission longer, compared to participants in the low‐dose group. <a href="./references#CD000544-bbs2-0032" title="PaoluziOA , IacopiniF , PicaR , CrispinoP , MarcheggianoA , ConsolazioA , et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics2005;21(9):1111-9. PaoluziOA , PicaR , CrispinoP , IacopiniF , ConsolazioA , RiveraM , et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology2005;128(4 Suppl 2):A585. ">Paoluzi 2005</a> recommended a dosage of 2.4 g/day due to the significantly longer time to relapse in the higher‐dosage group. <a href="./references#CD000544-bbs2-0034" title="PicaR , CassieriC , CoccoA , MarcheggianoA , OcchigrossiG , ZippiM , et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis. Italian Journal of Medicine2012;1:108. ">Pica 2012</a> compared 4.8 g/day to 2.4 g/day and found no difference in relapse rates between groups. Further research may be needed to determine the ideal dosage of Asacol for maintenance therapy. </p> <p>Three studies compared the efficacy of high‐dose balsalazide (4.0 g/day to 6.0 g/day) to low dose balsalazide (2.0 g/day to 3.0 g/day). <a href="./references#CD000544-bbs2-0010" title="GiafferMH , HoldsworthCD , Lennard-JonesJE , RodriguesCA , McIntyrePB , ManjunathaS , et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics1992;6:479-85. ">Giaffer 1992a</a> found balsalazide 4.0 g/day to be significantly superior to 2.0 g/day for preventing relapses over 12 months. There were no differences in safety between groups noted. A pooled analysis of two studies comparing balsalazide 6.0 g/day to 3.0 g/day found no significant difference in relapse rates. However, these results should be interpreted with caution due to a high degree of heterogeneity and sparse data. The high degree of heterogeneity was due to the two studies having conflicting results. <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a> found no differences in relapse rates between the 6.0 g/day and 3.0 g/day groups at either six or 12 months. <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a> noted no differences in safety. <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a> found 6.0 g/day to be superior to 3 g/day for preventing relapse over 26 weeks with no differences in safety. Differences in patient populations may explain these findings. <a href="./references#CD000544-bbs2-0012" title="GreenJR , SwanCH , RowlinsonA , GibsonJA , BrownP , KerrGD , et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics1992;6:647-52. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology1992;102(4 Part 2):A631. ">Green 1992</a> included participants with a very distal extent of UC and a large proportion of participants had long‐term remission at entry (e.g. greater than one year). <a href="./references#CD000544-bbs2-0024" title="KruisW , SchreiberS , TheuerD , BrandesJW , SchutzE , HowaldtS , et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut2001;49(6):783-9. ">Kruis 2001</a> suggested that people with more extensive UC or with frequent relapses may benefit from a higher dose of maintenance therapy. </p> <p><a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a> investigated different doses of once‐daily Salofalk (3 g or 1.5 g) and found that significantly fewer participants relapsed at 12 months in the group receiving 3 g once‐daily (25%) group compared to participants in the 1.5 g group (39%). This analysis involved 439 participants and provided moderate‐certainty evidence (based on GRADE analysis) that 3 g Salofalk once daily is superior to 1.5 g Salofalk once daily for maintenance treatment of UC. There were no differences in safety between groups. In a post hoc analysis, <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a> observed that participants with active inflammation at baseline in the 3 g group continued to maintain a higher rate of remission than participants receiving lower doses (i.e. 1.5 g once daily or 0.5 g three times daily). <a href="./references#CD000544-bbs2-0025" title="KruisW , GreinwaldR , MuellerR . Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2013;144(5 Suppl 1):S768. KruisW , JonaitisL , PokrotnieksJ , AcuteG , MikhailovaTL , HorynskiM , et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology2008;134(4 Suppl 1):A489. KruisW , JonaitisL , PokrotnieksJ , MikhailovaTL , HorynskiM , BátovskýM , et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics2011;33(3):313-22. ">Kruis 2011</a> concluded that 3 g once daily is an appropriate dose for maintenance of remission, and may be beneficial for people with signs of inflammation or in whom endoscopic data are not available. No other maintenance studies looked at dose‐ranging for once‐daily treatment using other 5‐ASA formulations. </p> <p><a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a> compared the efficacy of olsalazine 2.0 g/day to 1.0 g/day and 0.5 g/day. There was no significant difference in relapse at 12 months between the 2.0 g/day and 1.0 g/day groups. A dosage of 2.0 g/day was significantly superior to 0.5 g/day for preventing relapse. There were no differences in safety noted. Subgroup analysis showed that participants with proctitis and recent relapse may benefit from a dosage of 2.0 g/day (<a href="./references#CD000544-bbs2-0042" title="TravisSP , TyskC , deSilvaHJ , Sandberg-GertzenH , JewellDP , JarnerotG . Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut1994;35:1282-6. ">Travis 1994</a>). <a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a> compared the efficacy of Pentasa 3.0 g/day to 1.5 g/day. Although there was a trend favoring the higher dose, there was no significant difference in prevention of relapse over one year. The higher dosage was not associated with a higher incidence of AEs (<a href="./references#CD000544-bbs2-0009" title="FockensP , MulderCJ , FerwadaJ , TytgatGN , the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa). Gastroenterology1993;104:A701. FockensP , MulderCJ , TytgatGN , BlokP , FerwerdaJ , MeuwissenSG , et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology1995;7(11):1025-30. ">Fockens 1995</a>). </p> </section> <section id="CD000544-sec-0088"> <h3 class="title" id="CD000544-sec-0088">Overall completeness and applicability of evidence</h3> <p>Evidence presented in this review is applicable to most patients with mild‐to‐moderate UC. The review examined 5‐ASA compared to placebo, SASP, and comparator 5‐ASA. The review also examined 5‐ASA dose‐ranging studies and once‐daily compared to conventional‐dosing studies. All the efficacy and safety outcomes we aimed to report on were included in the studies. The review found the efficacy outcomes for 5‐ASA versus placebo, 5‐ASA versus SASP, and once‐daily versus conventional dosing to be of moderate‐ to high‐certainty evidence. Therefore, this implies this area does not need additional studies. However, the evidence regarding the safety outcomes for most comparisons ranged from very low to moderate. In addition, the efficacy outcomes for the oral 5‐ASA versus comparator 5‐ASA and high‐dose versus low‐dose oral 5‐ASA ranged from low to moderate. Therefore, additional studies assessing these efficacy and safety outcomes may change the overall results. </p> </section> <section id="CD000544-sec-0089"> <h3 class="title" id="CD000544-sec-0089">Quality of the evidence</h3> <p>Fourteen studies were at low risk and 30 studies were at unclear risk for randomization because the methods of randomization were not described. Twenty‐five studies were at low risk and 19 studies were at unclear risk for allocation concealment because the methods were not adequately described. Thirty‐two studies were double blind and at low risk of bias. One study was at unclear risk because the placebo capsules were not described in detail and 10 studies were at high risk of bias because they were either single blind or open label. Thirty‐one studies were at low risk of bias and thirteen studies were at unclear risk for incomplete outcome data because the number of dropouts or reasons for withdrawal (or both) were not provided. </p> <p>For the oral 5‐ASA versus placebo comparison, the certainty of the evidence for the outcome failure to maintain clinical or endoscopic remission was high. The certainty of the evidence for the outcomes AEs, withdrawal due to AEs, and exclusion/withdrawal after entry was moderate due to sparse data, and SAEs was low due to very sparse data (<a href="./full#CD000544-tbl-0001">summary of findings Table 1</a>). For the studies comparing 5‐ASA with SASP, the certainty of the evidence for the outcome failure to maintain clinical or endoscopic remission was high. The certainty of the evidence for AEs, withdrawal due to AEs, and exclusion/withdrawal after entry was moderate due to sparse data (<a href="./full#CD000544-tbl-0002">summary of findings Table 2</a>). For the studies comparing once‐daily dosing to conventional dosing for maintenance of remission in UC, the certainty of the evidence for failure to maintain clinical or endoscopic remission, AEs, and exclusion/withdrawal after entry was high. The certainty of the evidence for SAEs and failure to adhere to study medication outcomes was moderate due to sparse data, and lastly, withdrawal due to AEs was low due to sparse data and risk of bias (<a href="./full#CD000544-tbl-0003">summary of findings Table 3</a>). For the studies comparing different oral 5‐ASA formulations the certainty of the evidence for exclusion/withdrawal after entry was moderate due to sparse data. Failure to maintain clinical or endoscopic remission, AEs, and SAEs were rated as low‐certainty evidence due to sparse data and risk of bias. Withdrawal due to AEs was very low‐certainty evidence due to very sparse data and risk of bias (<a href="./full#CD000544-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD000544-sec-0090"> <h3 class="title" id="CD000544-sec-0090">Potential biases in the review process</h3> <p>The methods and reporting of this review were based on the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000544-bbs2-0104" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). We conducted a comprehensive literature search and two review authors independently screened the studies, extracted the data, assessed the risk of bias, and performed a GRADE analysis to minimize the bias. Despite these standardized processes, there are some potential limitations to making general conclusions from this review. Almost every study utilized a unique clinical or endoscopic index. Unlike Crohn's disease, the lack of standard indices in UC prevented the collection of consistent treatment efficacy data and makes comparisons across clinical studies difficult. In addition, results were periodically obscured in several studies that failed to specify the treatment arm to which certain excluded participants were initially randomized. </p> </section> <section id="CD000544-sec-0091"> <h3 class="title" id="CD000544-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>We identified two other systematic reviews that assessed the use of 5‐ASA for maintenance of remission in UC (<a href="./references#CD000544-bbs2-0097" title="FordAC , AchkarJP , KhanKJ , KaneSV , TalleyNJ , MarshallJK , et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology2011;106:601-16.">Ford 2011a</a>; <a href="./references#CD000544-bbs2-0098" title="FordAC , KhanKJ , SandbornWJ , KaneSV , MoayyediP . Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology2011;106:2070-7.">Ford 2011b</a>). </p> <p><a href="./references#CD000544-bbs2-0097" title="FordAC , AchkarJP , KhanKJ , KaneSV , TalleyNJ , MarshallJK , et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology2011;106:601-16.">Ford 2011a</a> is a systematic review and meta‐analysis assessing the efficacy of 5‐ASA in people with UC. The review identified 11 trials of 5‐ASAs compared to placebo in people with quiescent UC. The review concluded 5‐ASA was highly effective for preventing relapse in UC and there was no difference between the types of 5‐ASA therapy (SASP, olsalazine) used for preventing relapse in UC. The review also suggested that 5‐ASA doses of 2.0 g/day or greater have greater efficacy in comparison to the other doses. The results of our current Cochrane Review agree with the Ford review. We also found that the 5‐ASA group had lower relapse rates compared to the placebo group. </p> <p><a href="./references#CD000544-bbs2-0098" title="FordAC , KhanKJ , SandbornWJ , KaneSV , MoayyediP . Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology2011;106:2070-7.">Ford 2011b</a> is a systematic review and meta‐analysis that studied once‐daily dosing compared to conventional dosing for people with quiescent UC taking 5‐ASAs. The results showed that the relapse rates, non‐compliance, and AEs did not differ between the once‐daily and conventional dosing schedules. The study concluded that once‐daily dosing is as effective as conventional dosing for the prevention of relapse in people with UC. The results of this current Cochrane Review also concluded there are no differences in the relapse, non‐compliance/adherence, and AE rates between the once‐daily and conventional dosing groups. Therefore, the results of both reviews agree with each other. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000544-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000544-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD000544-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 1: Failure to maintain clinical or endoscopic remission at 6–12 months" data-id="CD000544-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 1: Failure to maintain clinical or endoscopic remission at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 2: Development of any adverse event at 6–12 months" data-id="CD000544-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 2: Development of any adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 3: Development of any adverse event (sensitivity analysis) at 6–12 months" data-id="CD000544-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 3: Development of any adverse event (sensitivity analysis) at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 4: Development of any serious adverse event at 6–12 months" data-id="CD000544-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 4: Development of any serious adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 5: Withdrawal from study due to adverse event at 6–12 months" data-id="CD000544-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 5: Withdrawal from study due to adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 6: Withdrawal from study due to adverse event (sensitivity analysis) at 6–12 months" data-id="CD000544-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 6: Withdrawal from study due to adverse event (sensitivity analysis) at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 7: Exclusion/withdrawal after entry (not due to relapse) at 6–12 months" data-id="CD000544-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: 5‐Aminosalicylic acid (5‐ASA) versus placebo, Outcome 7: Exclusion/withdrawal after entry (not due to relapse) at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 1: Failure to maintain clinical or endoscopic remission at 6–18 months" data-id="CD000544-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 1: Failure to maintain clinical or endoscopic remission at 6–18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 2: Failure to maintain remission (trials without olsalazine) at 6–12 months" data-id="CD000544-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 2: Failure to maintain remission (trials without olsalazine) at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 3: Development of any adverse event at 6–18 months" data-id="CD000544-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 3: Development of any adverse event at 6–18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 4: Withdrawal from study due to adverse event at 6–18 months" data-id="CD000544-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 4: Withdrawal from study due to adverse event at 6–18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 5: Exclusion/withdrawal after entry (not due to relapse) at 6–18 months" data-id="CD000544-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: 5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP), Outcome 5: Exclusion/withdrawal after entry (not due to relapse) at 6–18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 1: Failure to maintain clinical or endoscopic remission at 6 months" data-id="CD000544-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 1: Failure to maintain clinical or endoscopic remission at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 2: Failure to maintain clinical or endoscopic remission at 12–13 months" data-id="CD000544-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 2: Failure to maintain clinical or endoscopic remission at 12–13 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 3: Failure to adhere to study medication regimen at study endpoint at 6–13 months" data-id="CD000544-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 3: Failure to adhere to study medication regimen at study endpoint at 6–13 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 4: Failure to adhere to study medication regimen at 6–13 months (sensitivity analysis – excluding outliers)" data-id="CD000544-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 4: Failure to adhere to study medication regimen at 6–13 months (sensitivity analysis – excluding outliers) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 5: Development of any adverse event at 6–13 months" data-id="CD000544-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 5: Development of any adverse event at 6–13 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 6: Development of serious adverse events at 6–13 months" data-id="CD000544-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 6: Development of serious adverse events at 6–13 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 7: Withdrawal due to adverse event at 6–13 months" data-id="CD000544-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 7: Withdrawal due to adverse event at 6–13 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 8: Exclusion/withdrawal after entry (not due to relapse) at 6–13 months" data-id="CD000544-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID]), Outcome 8: Exclusion/withdrawal after entry (not due to relapse) at 6–13 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 1: Failure to maintain clinical or endoscopic remission at 6–18 months" data-id="CD000544-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 1: Failure to maintain clinical or endoscopic remission at 6–18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 2: Development of any adverse event at 6–12 months" data-id="CD000544-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 2: Development of any adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 3: Development of any serious adverse event at 12 months" data-id="CD000544-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 3: Development of any serious adverse event at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 4: Withdrawal from study due to adverse event at 6–12 months" data-id="CD000544-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 4: Withdrawal from study due to adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 5: Exclusion/withdrawal after entry (not due to relapse) at 6–12 months" data-id="CD000544-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: 5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA, Outcome 5: Exclusion/withdrawal after entry (not due to relapse) at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 1: Failure to maintain clinical or endoscopic remission at 6–18 months" data-id="CD000544-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 1: Failure to maintain clinical or endoscopic remission at 6–18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 2: Development of any adverse event at 6–12 months" data-id="CD000544-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 2: Development of any adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 3: Development of any serious adverse event at 6–12 months" data-id="CD000544-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 3: Development of any serious adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 4: Withdrawal from study due to adverse event at 6–12 months" data-id="CD000544-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 4: Withdrawal from study due to adverse event at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000544-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/urn:x-wiley:14651858:media:CD000544:CD000544-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 5: Exclusion/withdrawal after entry (not due to relapse) at 6–12 months" data-id="CD000544-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_t/tCD000544-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: 5‐Aminosalicylic acid (5‐ASA) (dose ranging), Outcome 5: Exclusion/withdrawal after entry (not due to relapse) at 6–12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/media/CDSR/CD000544/image_n/nCD000544-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000544-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus placebo for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral 5‐ASA vs placebo for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent UC<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> oral 5‐ASA<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/>(334 to 416) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b><br/>(0.61 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1555<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission defined using the revised SDAI (rectal bleeding = 0, mucosal appearance ≤ 2). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b><br/>(292 to 472) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/>(0.73 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1132<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events included headache, nausea, abdominal pain, dyspepsia, bloating, influenza syndrome, rhinitis, diarrhea, and nasopharyngitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> <p>(3 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.19 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>826</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included UC aggravation, acute pancreatitis, moderate ventricular dysfunction, intestinal obstruction, and esophagitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse event</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(34 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/>(0.76 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1454<br/>(7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included UC aggravation diarrhea, headache, and paresthesia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b> </p> <p>(162 to 266)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> </p> <p>(0.88 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1074</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SDAI:</b> Sutherland Disease Activity Index; <b>UC:</b> ulcerative colitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious imprecision (478 events).<br/><sup>b</sup>Downgraded two levels due to very serious imprecision (11 events).<br/><sup>c</sup>Downgraded one level due to serious imprecision (70 events).<br/><sup>d</sup>Downgraded one level due to serious imprecision (202 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus placebo for maintenance of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000544-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus sulfasalazine for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral 5‐ASA vs SASP for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent ulcerative colitis<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> oral 5‐ASA<br/><b>Comparison:</b> SASP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SASP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>489 per 1000</b><br/>(441 to 544) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/>(1.03 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1655<br/>(12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or endoscopic remission defined as the absence of colitis symptoms together with an absence of inflammation on sigmoidoscopy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b><br/>(130 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> <br/>(0.82 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1138<br/>(7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Commonly reported adverse events in the SASP‐controlled trials included: headache, anorexia or appetite loss, nausea, vomiting, abdominal pain, dyspepsia, excessive flatus, bloating, urticaria, and rash. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse event</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/>(47 to 102) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> <br/>(0.87 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1585<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included diarrhea, abdominal pain, indigestion, and rash. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> <p>(160 to 251)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b> </p> <p>(1.04 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1497</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SASP:</b> sulfasalazine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision (182 events).<br/><sup>b</sup>Downgraded one level due to imprecision (97 events).<br/><sup>c</sup>Downgraded one level due to imprecision (259 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus sulfasalazine for maintenance of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000544-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Once‐daily dosing versus conventional dosing for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Once‐daily dosing vs conventional dosing for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent UC<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> OD oral 5‐ASA<br/><b>Comparison:</b> conventional dosing of 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Conventionally dosed oral <b>5</b>‐ASA </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>OD oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 12–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b><br/>(344 to 395) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.88 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3910<br/>(10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or endoscopic remission defined as a mucosal score of 0 or 1 (endoscopic remission), or a bloody stool score of 0 and an UC‐DAI &lt; 2/Simple Clinical Colitis Activity Index score of ≤ 2 points (clinical remission). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication regimen</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b><br/>(52 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/>(0.72 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2306<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence to medication regimen calculated using objective data (pill count or pharmacy data) in 6/9 studies in the analysis. 2 studies used participant self‐report to calculate adherence and 1 study did not describe how adherence was assessed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>481 per 1000</b><br/>(451 to 510) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/>(0.92 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3497<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events included flatulence, dyspepsia, abdominal pain, nausea, diarrhea, headache, nasopharyngitis, inflammation of the upper respiratory tract, gastroenteritis. dental caries, and worsening of UC. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> <p>(17 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> </p> <p>(0.77 to 1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3196</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included UC aggravation, acute pancreatitis, anal fistula, pneumonia, melena, nephrolithiasis, and hypersensitivity pneumonitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(11 to 27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/>(0.74 to 1.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4340<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included UC aggravation, flatulence, nausea, and abdominal distension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–13 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> <p>(127 to 172)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> </p> <p>(0.85 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3737</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>OD:</b> once daily; <b>RR:</b> risk ratio; <b>SDAI:</b> Sutherland Disease Activity Index; <b>UC:</b> ulcerative colitis; <b>UC‐DAI:</b> Ulcerative Colitis Disease Activity Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision (190 events).<br/><sup>b</sup>Downgraded one level due to imprecision (76 events).<br/><sup>c</sup>Downgraded one level due to imprecision (67 events).<br/><sup>d</sup>Downgraded two levels due to risk of bias (two studies open label and high risk of bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Once‐daily dosing versus conventional dosing for maintenance of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000544-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus comparator 5‐aminosalicylic acid formulation for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral 5‐ASA vs comparator 5‐ASA formulation for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with quiescent UC<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> oral 5‐ASA (balsalazide, Pentasa and olsalazine)<br/><b>Comparison:</b> comparator oral 5‐ASA (Asacol and Salofalk) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator Oral 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to maintain clinical or endoscopic remission</b> </p> <p>Follow‐up: 6–18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>407 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b><br/>(370 to 521) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.91 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>707<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or endoscopic remission was defined as either the Harvey Bradshaw Index (score &lt; 3) and by a sigmoidoscopy (score 0–1) or the absence of symptoms or the presence of only mild symptoms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to study medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>686 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>645 per 1000</b><br/>(569 to 734) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.83 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events included dyspepsia, abdominal pain, nausea, distension, diarrhea, headache, nasopharyngitis or respiratory infections, influenza‐like disorder, and rash. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> <p>(15 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b> </p> <p>(0.14 to 2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events reported included urinary tract infection, severe complication of UC, cardiac arrest, ischemic heart, fracture of the scaphoid, and spigelian hernia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><br/>(25 to 124) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> <br/>(0.0.56 to 2.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included headache, lethargy, hypertension, malaise, and abdominal pain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion/withdrawal after entry</b> </p> <p>Follow‐up: 6–12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> </p> <p>(200 to 378)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> </p> <p>(0.90 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) come from control arm of meta‐analysis, based on included trials. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>5‐ASA:</b> 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>OD:</b> once daily; <b>RR:</b> risk ratio; <b>SDAI:</b> Sutherland Disease Activity Index; <b>UC:</b> ulcerative colitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious imprecision (300 events).<br/><sup>b</sup>Downgraded one level due to risk of bias. Two studies in pooled analysis were single blind and one was open label.<br/><sup>c</sup>Downgraded one level due to serious imprecision (236 events).<br/><sup>d</sup>Downgraded one level due to risk of bias. One study in the pooled analysis was open label.<br/><sup>e</sup>Downgraded two levels due to serious imprecision (8 events).<br/><sup>f</sup>Downgraded two levels due to very serious imprecision (23 events).<br/><sup>g</sup>Downgraded one level due to risk of bias. One study in the pooled analysis due was single blind and another was open label.<br/><sup>h</sup>Downgraded one level due to imprecision (114 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral 5‐aminosalicylic acid versus comparator 5‐aminosalicylic acid formulation for maintenance of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/full#CD000544-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000544-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Failure to maintain clinical or endoscopic remission at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.61, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Dose of 5‐ASA: &lt; 1 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.59, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Dose of 5‐ASA: 1–1.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Dose of 5‐ASA: ≥ 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.60, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Development of any adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Dose of 5‐ASA: &lt; 1 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.51, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Dose of 5‐ASA: 1–1.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Dose of 5‐ASA: ≥ 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.14, 20.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Development of any adverse event (sensitivity analysis) at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Dose of 5‐ASA: &lt; 1 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.51, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Dose of 5‐ASA: 1–1.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Dose of 5‐ASA: ≥ 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.25, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Development of any serious adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.19, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Dose of 5‐ASA: &lt; 1 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.03, 7.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Dose of 5‐ASA: 1–1.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.18, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Withdrawal from study due to adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.76, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Dose of 5‐ASA: &lt; 1 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.15, 13.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Dose of 5‐ASA: 1–1.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.54, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Dose of 5‐ASA: ≥ 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.78, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Withdrawal from study due to adverse event (sensitivity analysis) at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.50, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Dose of 5‐ASA: &lt; 1 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.15, 13.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Dose of 5‐ASA: 1–1.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.54, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Dose of 5‐ASA: ≥ 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Exclusion/withdrawal after entry (not due to relapse) at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.88, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Dose of 5‐ASA: &lt; 1 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Dose of 5‐ASA: 1–1.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.87, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Dose of 5‐ASA: ≥ 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.69, 2.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000544-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Failure to maintain clinical or endoscopic remission at 6–18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.03, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Failure to maintain remission (trials without olsalazine) at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.92, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Development of any adverse event at 6–18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.82, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Withdrawal from study due to adverse event at 6–18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.87, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Exclusion/withdrawal after entry (not due to relapse) at 6–18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.04, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) versus sulfasalazine (SASP)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000544-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID])</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Failure to maintain clinical or endoscopic remission at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Asacol (OD vs BID or TID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.83, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 MMX (OD) vs Asacol (BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.75, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Failure to maintain clinical or endoscopic remission at 12–13 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Asacol (OD vs BID or TID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 MMX (OD) vs Asacol (BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.74, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Pentasa (OD vs BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 MMX (OD vs BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.87, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Salofalk granules (OD vs TID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Failure to adhere to study medication regimen at study endpoint at 6–13 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.72, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Failure to adhere to study medication regimen at 6–13 months (sensitivity analysis – excluding outliers) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.92, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Development of any adverse event at 6–13 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Development of serious adverse events at 6–13 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.77, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Withdrawal due to adverse event at 6–13 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.74, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Exclusion/withdrawal after entry (not due to relapse) at 6–13 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.85, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Once‐daily (OD) versus conventional dosing (twice [BID] or three times daily [TID])</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000544-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Failure to maintain clinical or endoscopic remission at 6–18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.91, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.87, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.86, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Development of any adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.51, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Development of any serious adverse event at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.14, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.14, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Withdrawal from study due to adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.56, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.61, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.16, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Exclusion/withdrawal after entry (not due to relapse) at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.90, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.81, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.76, 2.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) versus comparator 5‐ASA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000544-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) (dose ranging)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Failure to maintain clinical or endoscopic remission at 6–18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Asacol 4.8 g vs 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.46, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Asacol 3.2 g vs 2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.83, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Asacol 2.4 g vs 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 Asacol 1.6 g vs 0.8 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.78, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.5 Balsalazide 6.0 g vs 3.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.21, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.6 Balsalazide 4.0 g vs 2.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.45, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.7 Olsalazine 2.0 g vs 1.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.66, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.8 Salofalk granules 3 g vs 1.5 g once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.49, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.9 Pentasa 3.0 g vs 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.48, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Development of any adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Asacol 2.4 g vs 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.12, 68.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Asacol 1.6 g vs 0.8 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.18, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Balsalazide 6.0 g vs 3.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.88, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.4 Olsalazine 2.0 g vs 1.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.94, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.5 Salofalk granules 3 g vs 1.5 g once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.61, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Development of any serious adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.43, 2.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Asacol 1.6 g vs 0.8 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.43, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Withdrawal from study due to adverse event at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.53, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Asacol 2.4 g vs 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.12, 68.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Asacol 1.6 g vs 0.8 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.3 Balsalazide 6.0 g vs 3.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.21, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.4 Balsalazide 4.0 g vs 2.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.54, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.5 Salofalk granules 3 g vs 1.5 g once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.29, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.6 Pentasa 3.0 g vs 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.07, 16.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Exclusion/withdrawal after entry (not due to relapse) at 6–12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Asacol 2.4 g vs 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.38, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Asacol 1.6 g vs 0.8 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.80, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.3 Balsalazide 6.0 g vs 3.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.4 Balsalazide 4.0 g vs 2.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.77, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.5 Olsalazine 2.0 g vs 1.0 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.83, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.6 Salofalk granules 3 g vs 1.5 g once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.46, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.7 Pentasa 3.0 g vs 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.44, 1.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">5‐Aminosalicylic acid (5‐ASA) (dose ranging)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000544.pub5/references#CD000544-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000544.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000544-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000544-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000544-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000544-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD000544-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD000544-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD000544-note-0012">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000544-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000544\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000544\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000544\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000544\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000544\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000544.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000544.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000544.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000544.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000544.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724864670"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000544.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724864674"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000544.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6d3ac8e4f4ca',t:'MTc0MDcyNDg2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 